



```
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Putative matrix cell adhesion molecule-3.
OS Homo sapiens (human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Tilson M.D.;
RL Submitted (JUN-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AJ039025; AAK82649.1; -.
DR HSSP; P01869; 1AE6.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PSS0835; IG_LIKE; 1.
SQ SEQUENCE 159 AA; 17497 MW; 5D29537E881FAF02 CRC64;

Query Match 65.4%; Score 390.5; DB 2; Length 159;
Best Local Similarity 60.0%; Pred. No. 3,1e-33;
Matches 78; Conservative 16; Mismatches 19; Indels 17; Gaps 2;

QY 1 VOLLESGAEVKKRPGASVTISCSQASRODPFGQYIHWVROAPGCGFEMMGIIINSGGSANY 60
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 21 VOLV-OSGAEVKKRPGASVSKASGYTFSNYYMMVROAPGCGPEMMGVINSGGSARY 79
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 APFKGRLTMSRDSSTDTVYMTLTSLSDDTAAYVYCCLO-----ALKHW 104
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 80 AQKFGRLTMRDSTSTVYMTLSLSDDTAAYFCAREMETITFGCAVSKGYFYGGMDV 139
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 105 GQGTLVAVSS 114
   |||:|||||
Db 140 GQGTLTVSS 149
   |||:|||||

RESULT 3
HVLB_HUMAN STANDARD; PRT; 117 AA.
ID P01743;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE IG heavy chain V-I region H3 precursor.
OS Homo sapiens (human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=83144028; PubMed=6298778;
RA Rechavi G., Ram D., Glazer L., Zakut R., Givol D.;
RT "Evolutionary aspects of immunoglobulin heavy chain variable region
   (VH) gene subgroups."
RL Proc. Natl. Acad. Sci. U.S.A. 80:855-859(1983).
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.ebi.ac.uk/announcements
CC or send an email to license@ebi.ac.uk).
CC -----
CC EMBL; J00240; AAA52988.1; -.
DR PIR; A02024; HVHUNG.
DR HSSP; P01751; 1NOB.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF00447; IG; 1.
```

```
DR SMART; SM00406; IGV; 1.
DR PROSITE; PSS0835; IG_LIKE; 1.
KW Immunoglobulin V region; Signal.
FT SIGNAL 1 19
FT CHAIN 20 117
FT DOMAIN 20 >117
FT NON TER 117 117
SQ SEQUENCE 117 AA; 12946 MW; 2D3F92FC60CD1FE7 CRC64;

Query Match 63.2%; Score 376.5; DB 1; Length 117;
Best Local Similarity 74.0%; Pred. No. 6.6e-32;
Matches 71; Conservative 12; Mismatches 12; Indels 1; Gaps 1;

QY 1 VOLLESGAEVKKRPGASVTISCSQASRODPFGQYIHWVROAPGCGFEMMGIIINSGGSANY 60
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 21 VOLV-OSGAEVKKRPGASVSKASGYTFSNYYMMVROAPGCGLEMMGVINSGGSSTY 79
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 APFKGRLTMSRDSSTDTVYMTLTSLSDDTAAYVYCC 96
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 80 AQKFGRLTMRDSTSTVYMTLSLSDDTAAYVYCC 115
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 4
Q9UL95 PRELIMINARY; PRT; 125 AA.
ID Q9UL95;
AC Q9UL95;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
   (fragment).
OS Homo sapiens (human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/cclin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
   fetus."
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR EMBL; AF035019; AAD56255.1; -.
DR HSSP; P01751; 1NOB.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PSS0835; IG_LIKE; 1.
FT NON TER 1 1
FT NON TER 125 125
SQ SEQUENCE 125 AA; 13516 MW; 0D3CD5C232488BAC CRC64;

Query Match 62.4%; Score 372; DB 2; Length 125;
Best Local Similarity 58.4%; Pred. No. 2,1e-31;
Matches 73; Conservative 15; Mismatches 25; Indels 12; Gaps 2;

QY 1 VOLLESGAEVKKRPGASVTISCSQASRODPFGQYIHWVROAPGCGFEMMGIIINSGGSANY 60
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 2 VOLV-OSGAEVKKRPGASVSKASGYTFGYMMHWVROAPGCGLEMMGVINSGGSNTY 60
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 APFKGRLTMSRDSSTDTVYMTLTSLSDDTAAYVYCCLO-----QALKHWGQGT 109
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AQKFGRLTMRDSTSTVYMTLSLSDDTAAYVYCARSGGRIAAAGDAPIMWGQTM 120
   |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 5
Q6N095 PRELIMINARY; PRT; 475 AA.
ID Q6N095
```

AC O6N095;  
 DT 05-JUL-2004 (Tremblrel. 27, Created)  
 DT 05-JUL-2004 (Tremblrel. 27, Last sequence update)  
 DT 05-JUL-2004 (Tremblrel. 27, Last annotation update)  
 DE Hypothetical protein DKFZp686K03196.  
 GN Name=DKFZp686K03196;  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
 NC NCI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Human esophagus tumor;  
 RG The German Human cDNA Consortium;  
 RA Mambert R., Heubner D., Mewes H.W., Weil B., Amid C., Oeanger A.,  
 RA Fodor G., Han M., Wiemann S.;  
 RL Submitted (Aug-2003) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; BX640621; CAE45775.1; -  
 DR HSP; P01861; IADQ.  
 DR InterPro; IPR003599; IG\_1like.  
 DR InterPro; IPR007110; IG\_1like.  
 DR InterPro; IPR003597; IG\_C1.  
 DR InterPro; IPR003006; IG\_MHC.  
 DR InterPro; IPR003596; IG\_V.  
 DR Pfam; PF07654; C1-set; 3.  
 DR SMART; SM00409; IG; 2.  
 DR SMART; SM00407; IG; 3.  
 DR SMART; SM00406; IG; 1.  
 DR PROSITE; PSS0835; IG\_LIKE; 4.  
 DR PROSITE; PSS0290; IG\_MHC; UNKNOWN\_2.  
 KM Hypothetical protein\_  
 SQ SEQUENCE 475 AA; 52360 MW; 7BA14104CD2DB8F0 CRC64;

Query Match 62.0%; Score 369.5; DB 2; Length 475;  
 Best Local Similarity 61.1%; Pred. No. 1.8e-30;  
 Matches 77; Conservative 10; Mismatches 26; Indels 13; Gaps 2;

OY 1 VOLLESGAEVKKRPGASVTISCOASRODFSGQYIHWVROAPGCGFEMWGIINPSGGSANY 60  
 DB 21 VOLV-QSGADVKKRPGASVTKSCASGYSTFYIHWVROAPGCGLEWGMINPRSDSKTY 79  
 OY 61 APKFKRLTMSRSDSTDTVYMTLTSLTSEPTAVYCLQ-----LQALKGWGGT 108  
 DB 80 AQKFGKVTMTKDTSTVTFMELNSLKSGLTAIVYCTRDSSGRALMFGELDAFPIWGGT 139  
 OY 109 LVAVSS 114  
 DB 140 KTVSS 145  
 RESULT 6  
 O9UL94 PRELIMINARY; PRT; 119 AA.  
 AC O9UL94;  
 DT 01-MAY-2000 (Tremblrel. 13, Created)  
 DT 01-MAY-2000 (Tremblrel. 13, Last sequence update)  
 DT 01-OCT-2003 (Tremblrel. 25, Last annotation update)  
 DE Myosin-reactive immunoglobulin heavy chain variable region  
 DE (Fragment).  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
 NC NCI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RL MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;  
 RA Wu X., Liu B., Van der Merwe P.L., Kallis N.N., Berney S.M.,  
 RA Young D.C.;  
 RT "Myosin-reactive autoantibodies in rheumatic carditis and normal  
 fetus.";  
 RL Clin. Immunol. Immunopathol. 87:184-192(1998).  
 DR EMBL; AF035020; AAD56256.1; -  
 DR HSP; P01751; INQB.

DR InterPro; IPR007110; IG\_1like.  
 DR InterPro; IPR003596; IG\_V.  
 DR SMART; SM00406; IG; 1.  
 DR PROSITE; PSS0835; IG\_LIKE; 1.  
 FT NON\_TER 1  
 FT NON\_TER 119  
 SQ SEQUENCE 119 AA; 13205 MW; 13E64F5345FA16E CRC64;  
 Query Match 61.9%; Score 369; DB 2; Length 119;  
 Best Local Similarity 60.5%; Pred. No. 4.2e-31;  
 Matches 72; Conservative 16; Mismatches 25; Indels 6; Gaps 2;

OY 1 VOLLESGAEVKKRPGASVTISCOASRODFSGQYIHWVROAPGCGFEMWGIINPSGGSANY 60  
 DB 2 VOLV-QSGADVKKRPGASVTKSCASGYSTFYIHWVROAPGCGLEWGMINPRSDSKTY 94  
 OY 61 APKFKRLTMSRSDSTDTVYMTLTSLTSEPTAVYCLQ-----LQALKGWGGT 114  
 DB 61 AQKFGKVTMTKDTSTVTFMELNSLKSGLTAIVYCTRDSSGRALMFGELDAFPIWGGT 119

RESULT 7  
 O6N041 PRELIMINARY; PRT; 498 AA.  
 AC O6N041;  
 DT 05-JUL-2004 (Tremblrel. 27, Created)  
 DT 05-JUL-2004 (Tremblrel. 27, Last sequence update)  
 DT 05-JUL-2004 (Tremblrel. 27, Last annotation update)  
 DE Hypothetical protein DKFZp686O16217 (Fragment).  
 GN Name=DKFZp686O16217;  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
 NC NCI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Human rectum tumor;  
 RG The German Human cDNA Consortium;  
 RA Poustka A., Albert R., Moosmayer P., Schupp I., Wellenreuther R.,  
 RA Mewes H.W., Weil B., Amid C., Oeanger A., Fodor G., Han M., Wiemann S.;  
 RL Submitted (Aug-2003) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; BX640710; CAE45829.1; -  
 DR HSP; P01751; IASW.  
 DR InterPro; IPR003599; IG.  
 DR InterPro; IPR007110; IG\_1like.  
 DR InterPro; IPR003597; IG\_C1.  
 DR InterPro; IPR003006; IG\_MHC.  
 DR InterPro; IPR003596; IG\_V.  
 DR Pfam; PF07654; C1-set; 2.  
 DR SMART; SM00409; IG; 4.  
 DR SMART; SM00407; IG; 3.  
 DR SMART; SM00406; IG; 1.  
 DR PROSITE; PSS0835; IG\_LIKE; 4.  
 DR PROSITE; PSS0290; IG\_MHC; UNKNOWN\_2.  
 KM Hypothetical protein\_  
 FT NON\_TER 1  
 SQ SEQUENCE 498 AA; 54125 MW; 40B3208A84E03B46 CRC64;

Query Match 61.2%; Score 364.5; DB 2; Length 498;  
 Best Local Similarity 56.5%; Pred. No. 6.5e-30;  
 Matches 70; Conservative 20; Mismatches 23; Indels 11; Gaps 2;  
 OY 1 VOLLESGAEVKKRPGASVTISCOASRODFSGQYIHWVROAPGCGFEMWGIINPSGGSANY 60  
 DB 36 VOLV-QSGADVKKRPGASVTKSCASGYSTFYIHWVROAPGCGLEWGMINPRSDSKTY 94  
 OY 61 APKFKRLTMSRSDSTDTVYMTLTSLTSEPTAVYCLQ-----LQALKGWGGT 110  
 DB 95 AQKFGKVTMTKDTSTVTFMELNSLKSGLTAIVYCTRDSSGRALMFGELDAFPIWGGT 154  
 OY 111 AVSS 114  
 DB 155 TVSS 158

```
RESULT 8
HVIC_HUMAN STANDARD; PRT; 147 AA.
ID HVIC_HUMAN P01744;
DT 21-JUL-1986 (Rel. 01, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Ig heavy chain V-I region ND precursor (Fragments).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=83065234; PubMed=6815656;
RA Kenten J.H., Molgaard H.V., Houghton M., Derbyshire R.B., Viney J.,
RA Bell L.O., Gould H.J.;
RT "Cloning and sequence determination of the gene for the human
RT immunoglobulin epsilon chain expressed in a myeloma cell line.";
RT Proc. Natl. Acad. Sci. U.S.A. 79:6661-6665(1982).
RN [2]
RP SEQUENCE OF 20-147.
RA Bennich H.H., Johansson S.G.O., von Bahr-Lindstrom H.;
RL (in) Bach M.K. (eds.);
RL Immediate hypersensitivity: modern concepts and developments, pp.1-36,
RL Marcel Dekker, New York (1978).
CC -1- MISCELLANEOUS: This epsilon chain was isolated from a myeloma
CC protein.
CC -1- SIMILARITY: Contains 1 immunoglobulin-like domain.
DR HSSP: P01751; INOB.
DR GO: GO:0005576; C:extracellular; NAS.
DR GO: GO:0003823; F:antigen binding; NAS.
DR GO: GO:0006953; F:immune response; NAS.
DR InterPro: IPR007110; Ig_V.
DR SMART: SM00406; IGV; 1.
DR PROSITE: PS50835; IG_LIKE; 1.
DR PROSITE: PS50835; IG_LIKE; 1.
KM Direct protein sequencing; Immunoglobulin V region;
KW Pyroldione carboxylic acid; Signal.
FT SIGNAL 1 19
FT CHAIN 20 147 Ig heavy chain V-I region ND.
FT DOMAIN 20 131 Ig-like.
FT MOD_RES 20 20 Pyroldione carboxylic acid.
FT DISULFID 41 115
FT CONFLICT 21 21 T -> V (in Ref. 2).
FT CONFLICT 53 54 IH -> HI (in Ref. 2).
FT CONFLICT 67 68 VG -> GV (in Ref. 2).
FT CONFLICT 125 125 Missing (in Ref. 2).
FT NON_TER 147 147
SQ SEQUENCE 147 AA; 16491 MW; 948PFP72A5366C20 CRC64;

Query Match 59.7%; Score 356; DB 1; Length 147;
Best Local Similarity 54.4%; Pred. No. 1.3e-29;
Matches 68; Conservative 15; Mismatches 28; Indels 14; Gaps 1;

QY 4 LEQSGAEVRRPGASVYITSCQASRODFSGQYIHVWRQAPGGFEMGINSGSANYAPK 63
DB 23 LVQSGAEVRRPGASVYITSCQASGYTFIDSYIHWRQAPGHLEWGWININSGGTNAPR 82
QY 64 FKRGRLTMSRDSSTDTVYMTLTSLTSEDTAVVYCC-----ALQKMGCGTL 109
DB 83 FGGRVYMTIRDAFSTAYMDRLSLRSDSAVFCCKSPFSDYINPFIYTLIDWVGCGIT 142
QY 110 VAVSS 114
DB 143 VTWSS 147

RESULT 9
Q65ZC8 PRELIMINARY; PRT; 244 AA.
ID Q65ZC8
```

```
AC Q65ZC8;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE Single-chain Fv (fragment).
GN Name=scFv;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=97362799; PubMed=9219263;
RA Konemann R.E., Wing M.G., Winter G.;
RT "Complement recruitment using bispecific diabodies.";
RL Nat. Biotechnol. 15:629-631(1997).
DR EMBL; Y13057; CAA73500.1; -.
DR InterPro: IPR003599; Ig.
DR InterPro: IPR007110; Ig_V.
DR InterPro: IPR003596; Ig_V.
DR Pfam: PR00047; IGV; 2.
DR SMART; SM00409; IGV; 2.
DR SMART; SM00406; IGV; 2.
DR PROSITE; PS50835; IG_LIKE; 2.
FT NON_TER 1 1
FT NON_TER 244 244
SQ SEQUENCE 244 AA; 26127 MW; 4B1F17868338F2BF CRC64;

Query Match 59.1%; Score 352; DB 2; Length 244;
Best Local Similarity 56.2%; Pred. No. 6e-29;
Matches 68; Conservative 18; Mismatches 27; Indels 8; Gaps 2;

QY 1 VOLLEQSGAEVRRPGASVYITSCQASRODFSGQYIHVWRQAPGGFEMGINSGSANY 60
DB 2 VOLV-OSGAEVKKPGSVSVSCASGYTSDHMHVWRQAPGGLEWGWINDNCDTRF 60
QY 61 ARFKGRLTMSRDSSTDTVYMTLTSLTSEDTAVVYCC-----LQALQKMGCGTLVAVS 113
DB 61 AGRFGVYMTIRDTISAAVMEVSRIRSDDTAVVYCARGTGSAITGMVDVGGTLVTVS 120
QY 114 S 114
DB 121 S 121

RESULT 10
Q6N030 PRELIMINARY; PRT; 518 AA.
ID Q6N030;
AC Q6N030;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypochemical protein DKFZp686115212.
GN Name=DKFZp686115212;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX TISSUE=Human rectum tumor;
RA The German Human cDNA Consortium;
RA Pouskka A., Albert R., Moosmayer P., Schupp I., Wellenreuther R.,
RA Mewes H.W., Well B., Amlid C., Osanger A., Fobo G., Han M., Wiemann S.;
RL Submitted (Aug-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BX640724; CAA45841.1; -.
DR HSSP; P01861; IADQ.
DR InterPro: IPR000005; HTNARC.
DR InterPro: IPR003589; Ig.
DR InterPro: IPR007110; Ig_V.
DR InterPro: IPR003597; Ig_C1.
DR InterPro: IPR003006; Ig_MHC.
DR InterPro: IPR003596; Ig_V.
```

```

DR Pfam: PF07654; Cl-sect: 3.
DR SMART; SM00409; IG; 3.
DR SMART; SM00407; IGL1; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00041; HTH ARAC FAMILY_1; UNKNOWN_1.
DR PROSITE; PS00835; IG_Like; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 518 AA; 57019 MW; 93B5F96613BF6382 CRC64;

Query Match      58.4%; Score 348; DB 2; Length 518;
Best Local Similarity 57.1%; Pred. No. 3, 8e-28;
Matches 68; Conservative 15; Mismatches 28; Indels 8; Gaps 1

OY 4 LEQSGAEVVRPGASVTTISGQASRODPFGGYIHMVQAQPQGFEWNGIINPSGSANYAPK 63
    |||||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
DB 23 LVQSGAEVVKPKGASVKSCTAGYPFTNHFIWMVAQAPQSLEMMGMINTGNKTKYSQK 82
    |||||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
OY 64 FKGRITMRDSDSTDTVMYMTLTLTSEEDPAVVYCLLOA-----LKHWGGTILVAVSS 114
    |::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
DB 83 FQGRVTTIRDTWTTYTAAMDLSLRSEDPAIVVWCARDAPQGVTTYTFDYWGCGTTLTVASS 141
    |::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|

RESULT 11
O9GYZ2 PRELIMINARY; PRT; 119 AA.
ID O9GYZ2 AC O9GYZ2;
DT 01-MAR-2001 (TREMBLrel. 16, Created)
DT 01-MAR-2001 (TREMBLrel. 16, Last sequence update)
DT 01-OCT-2003 (TREMBLrel. 25, Last annotation update)
DE Monoclonal anti-idiotypic antibody NP30 heavy chain variable region
   (Fragment).
OS Schistosoma japonicum (Blood fluke).
OC Eukaryota; Metazoa; Platyhelminthes; Trematoda; Digenea; Strigeidida;
OC Schistosomatidae; Schistosomatidae; Schistosoma.
CX NCBI_TaxID=6182;
[1]
RN [1] SEQUENCE FROM N.A.
RP Song X.T., Feng Z.Q., Guan X.H.;
RA Submitted (JUN-2000) to the EMBL/GenBank/DDBJ databases.
RL EMBL: AF282622; AAC01452.1; -.
DR HSRP; P01751; 1A6W.
DR InterPro; IPRO07110; Ig-1like.
DR InterPro; IPRO03596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG_Like; 1.
FT NON_TER 1
FT NON_TER 119
SQ SEQUENCE 119 AA; 13567 MW; BA893873FD5FA6AB CRC64;

Query Match      58.2%; Score 347; DB 2; Length 119;
Best Local Similarity 58.8%; Pred. No. 8, 9e-29;
Matches 70; Conservative 13; Mismatches 30; Indels 6; Gaps 2.

OY 1 VOLLEQSGAEVVRPGASVTTISGQASRODPFGGYIHMVQAQPQGFEWNGIINPSGSANY 60
    |||||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
DB 2 VOLVE-SGAEVRRKPKGASVRSVCCKASGYFTFYNNMVAQAPQHGHLEWIGYINPSRGYNY 60
    |||||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
OY 61 APKFGRITMRDSDSTDTVMYMTLTLTSEEDPAVVYCLL-----QALKHWGGTILVAVSS 114
    |||||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
DB 61 NQFKRVDRTWTMDSKSFSTAAMDLSLRSAADSAAVYYCARYDDHYCLDYWGCGTTLTVASS 119

RESULT 12
O8WY24 PRELIMINARY; PRT; 497 AA.
ID O8WY24 AC O8WY24;
DT 01-MAR-2002 (TREMBLrel. 20, Created)
DT 01-MAR-2002 (TREMBLrel. 20, Last sequence update)
DT 01-MAR-2004 (TREMBLrel. 26, Last annotation update)
DE SMC66 protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
```

Query Match	Best Local Similarity	Score	DB 2	Length	497
Matches	67	Conservative	17	Mismatches	27
				Indels	11
				Gaps	1
OC Mammalia; Eutheria; Primates; Carnivora; Homiidae; Homo.					
OX NCBI_TaxID=9606;					
RN (1)					
RP SEQUENCE FROM N.A.					
RA Zheng S., Shao X., Cao J., Geng L., Fang Y., Dong Q.					
RL Submitted (JUN-2000) to the EMBL/GenBank/DBJ databases.					
DR EMBL; AF283666; AAL36987.1; ..					
DR HSSP; P01876; IOWO.					
DR Pfam; PF07654; Cl-seet; 2.					
DR SMART; SM00406; IGV; 1.					
DR PROSITE; PS00835; IG_LIKE; 4.					
DR PROSITE; PS00290; IG_MHC; UNKNOWN; 1.					
SQ SEQUENCE 497 AA; 53665 MW; F24D08DFA5A663E5 CRC64;					
Query Match	57.3%	Score	341.5;	DB 2;	Length
Best Local Similarity	54.9%	Pred. No.	1.8e-27;		
Matches	67	Conservative	17	Mismatches	27
				Indels	11
				Gaps	1
OC Mammalia; Eutheria; Primates; Carnivora; Homiidae; Homo.					
OX NCBI_TaxID=9606;					
RN (1)					
RP SEQUENCE FROM N.A.					
RA Zheng S., Shao X., Cao J., Geng L., Fang Y., Dong Q.					
RL Submitted (JUN-2000) to the EMBL/GenBank/DBJ databases.					
DR EMBL; AF283666; AAL36987.1; ..					
DR HSSP; P01876; IOWO.					
DR Pfam; PF07654; Cl-seet; 2.					
DR SMART; SM00406; IGV; 1.					
DR PROSITE; PS00835; IG_LIKE; 4.					
DR PROSITE; PS00290; IG_MHC; UNKNOWN; 1.					
SQ SEQUENCE 497 AA; 53665 MW; F24D08DFA5A663E5 CRC64;					



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

## OM protein - protein search, using sw model

Run on: November 9, 2005, 05:52:18 ; Search time 39 Seconds

(without alignments)  
281.249 Million cell updates/sec

Title: US-09-936-964A-36

Perfect score: 596  
Sequence: 1 VQLLESGAEVRRPGASVTI.....YCLQLAKHMGQTLVAVSS 114Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0  
Maximum DB seq length: 200000000Post-processing: Minimum Match 0%  
Maximum Match 100%

Listing first 45 summaries

Database :

1: pir1:\*  
2: pir2:\*  
3: pir3:\*  
4: pir4:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	418	70.1	142	2 A32483	Ig heavy chain V r
2	398.5	66.9	118	2 S36265	Ig heavy chain V r
3	391	65.6	121	2 S20783	Ig heavy chain V r
4	388.5	65.2	135	2 S49530	anti-Sm antibody V
5	385	64.6	123	2 D33548	Ig heavy chain V-1
6	376.5	63.2	98	2 S26920	Ig heavy chain V r
7	376.5	63.2	117	1 HVH0HG	Ig heavy chain pre
8	374	62.8	126	2 I44151	Ig heavy chain V r
9	366.5	61.5	137	2 C41287	Ig heavy chain pre
10	365	61.2	129	2 S46393	Ig heavy chain V r
11	362	60.7	110	2 PH1669	Ig heavy chain V r
12	361.5	60.7	109	2 PH1668	Ig heavy chain V r
13	358.5	60.2	171	2 S23623	Ig heavy chain V r
14	358	60.1	129	2 A33548	Ig heavy chain V-1
15	356.5	59.8	120	2 PH0962	Ig heavy chain V r
16	356	59.7	143	1 E1HUND	Ig heavy chain pre
17	355.5	59.6	120	2 S31999	Ig heavy chain V r
18	354	59.4	125	2 PH0957	Ig heavy chain V r
19	353.5	59.3	136	2 S31600	Ig heavy chain V r
20	352.5	59.1	116	2 PH0959	Ig heavy chain V r
21	351	58.9	127	2 S34014	Ig heavy chain V r
22	350.5	58.8	128	2 PH0952	Ig heavy chain V r
23	350	58.7	119	2 PH0961	Ig heavy chain V r
24	349.5	58.6	98	2 S26938	Ig heavy chain V r
25	349.5	58.6	117	2 S18551	Ig heavy chain V r
26	349.5	58.6	125	2 S68170	Ig heavy chain V r
27	348.5	58.5	122	2 PH0958	Ig heavy chain V r
28	348.5	58.5	136	2 PH0536	Ig heavy chain V r
29	347.5	58.3	104	2 S69899	Ig heavy chain V r

30	347	58.2	127	2 PH0955	Ig heavy chain V r
31	344.5	57.8	126	2 B33548	Ig heavy chain V-1
32	344.5	57.8	132	2 PH0954	Ig heavy chain V r
33	344	57.7	108	2 PH1664	Ig heavy chain V r
34	343	57.6	133	2 C33548	Ig heavy chain V-1
35	343	57.6	135	2 PH0953	Ig heavy chain V r
36	343	57.6	627	2 S14683	Ig mu chain precu
37	342.5	57.5	122	2 C49590	Ig heavy chain V r
38	341.5	57.3	98	2 S26912	Ig heavy chain V r
39	341.5	57.3	136	2 PH0960	Ig heavy chain V r
40	340.5	57.1	119	2 D30562	Ig heavy chain V r
41	340.5	57.1	132	2 S31596	Ig heavy chain V r
42	340	57.0	104	2 PH1665	Ig heavy chain V r
43	339.5	57.0	116	2 S55542	Ig heavy chain V r
44	339.5	57.0	117	1 HVH035	Ig heavy chain pre
45	339.5	57.0	117	2 S31680	Ig heavy chain V r

## ALIGNMENTS

```
RESULT 1
A32483
Ig heavy chain V region - human (fragment)
C/Species: Homo sapiens (man)
C/Date: 12-Oct-1989 #sequence_revision 12-Oct-1989 #text_change 16-Aug-1996
C/Accession: A32483
R/Larrick, J.W.; Danielsson, L.; Brenner, C.A.; Abrahamson, M.; Fry, K.E.; Borrebaeck, C
Biochem. Biophys. Res. Commun. 160, 1250-1256, 1989
A/Title: Rapid cloning of rearranged immunoglobulin genes from human hybridoma cells usi
A/Reference number: A32483; MUID:89273586; PMID:2499327
A/Accession: A32483
A/Status: preliminary
A/Molecule type: mRNA
A/Residues: 1-142 <LAR>
A:Cross-references: GB:M26463
C/Superfamily: immunoglobulin V region; immunoglobulin homology
C/Keywords: heterocretamer; immunoglobulin
F:25-108/Domain: immunoglobulin homology <IMM>

Query Match          70.1%; Score 418; DB 2; Length 142;
Best Local Similarity 63.8%; Pred. No. 6, 5e-32;
Matches 81; Conservative 15; Mismatches 17; Indels 14; Gaps 2;

QY      1 VQLLESGAEVRRPGASVTISCQASRDPSGGYIHVWRQAPQGFEMWGIINPSGGSANY 60
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      12 VQLV-QSGAEVKKPGASVVKSCASGYPTNTYMHVWRQAPQGLEWNGIINPSGNTY 70
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

QY      61 ARKFKRLTMSRDSSTDTYVMTLTSISDTAVVYC-----LQLAKHMGCG 107
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db      71 AAKFGRLTMRDSTSTVYVMTLSISRSDTAIVVYCARBKATTFGLITGMQWGGG 130
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||

QY      108 TLVAVSS 114
      ||| |||
Db      131 TLTVVSS 137
      ||| |||

RESULT 2
S36265
Ig heavy chain V region (clone alpha-MC1-1) - human (fragment)
C/Species: Homo sapiens (man)
C/Date: 03-Feb-1994 #sequence_revision 03-Feb-1994 #text_change 23-Jul-1999
C/Accession: S36265
R/Griffiths, A.D.; Malmqvist, M.; Marks, J.D.; Bye, J.M.; Embleton, M.J.; McCafferty, J.
EMBO J. 12, 725-734, 1993
A/Title: Human anti-self antibodies with high specificity from phage display libraries.
A/Reference number: S36265; MUID:93178448; PMID:7679990
A/Accession: S36265
A/Status: preliminary; nucleic acid sequence not shown
A/Molecule type: mRNA
A/Residues: 1-118 <GRI>
A:Cross-references: EMBL:218846; NID:g33121; PIDN:CAA79298.1; PID:g939900
C/Superfamily: immunoglobulin V region; immunoglobulin homology
```











Page Blank (uspto)

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: November 9, 2005, 05:52:18 ; Search time 22 Seconds

(without alignments)

386,818 Million cell updates/sec

Title: US-09-936-964A-36

Perfect score: 596

Sequence: 1 VQLLEQSGAVKRGASVTI.....YCLLQALKHGGRTLVSS 114

Scoring table: BLOSUM62

Searched: Gapop 10.0 , Gapext 0.5

Total number of hits satisfying chosen parameters: 513545

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database : Issued Patents AA:\*

- 1: /cgn2\_6/ptodata/1/iaa/5A.COMB.pep:\*
- 2: /cgn2\_6/ptodata/1/iaa/5B.COMB.pep:\*
- 3: /cgn2\_6/ptodata/1/iaa/6A.COMB.pep:\*
- 4: /cgn2\_6/ptodata/1/iaa/6B.COMB.pep:\*
- 5: /cgn2\_6/ptodata/1/iaa/PTUS.COMB.pep:\*
- 6: /cgn2\_6/ptodata/1/iaa/backfile1.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	396.5	66.5	120	3	US-09-025-769B-36
2	396.5	66.5	120	3	US-09-025-769B-59
3	396.5	66.5	120	4	US-09-480-070A-36
4	396.5	66.5	120	4	US-09-480-070A-59
5	396.5	66.5	120	4	US-09-490-153-36
6	396.5	66.5	120	4	US-09-490-153-59
7	396.5	66.5	120	4	US-09-490-324-36
8	396.5	66.5	120	4	US-09-490-324-59
9	391	65.6	123	1	US-08-477-877B-94
10	391	65.6	123	2	US-08-472-281A-94
11	391	65.6	123	2	US-08-477-989B-94
12	389	65.3	117	3	US-09-025-769B-22
13	389	65.3	117	3	US-09-490-070A-22
14	389	65.3	117	4	US-09-490-153-22
15	389	65.3	117	4	US-09-490-324-22
16	380	63.8	470	4	US-09-859-053-28
17	376.5	63.2	97	2	US-08-290-592B-16
18	376.5	63.2	97	5	PCT-US96-09448-16
19	376.5	63.2	117	3	US-08-545-809A-128
20	373.5	62.7	116	2	US-08-561-521-41
21	373.5	62.7	116	5	PCT-US95-01219-11
22	373.5	62.7	135	1	US-08-137-117D-102
23	373.5	62.7	135	2	US-08-436-717-102
24	373	62.6	121	4	US-09-254-180C-7
25	369	61.9	119	4	US-07-946-421-28
26	369	61.9	119	4	US-09-438-954-4
27	368.5	61.8	97	5	PCT-US95-10053-13

28	368.5	61.8	135	1	US-08-137-117D-100	Sequence 100, App
29	368.5	61.8	135	2	US-08-436-717-100	Sequence 100, App
30	368	61.7	140	3	US-08-836-561-63	Sequence 63, Appl
31	368	61.7	140	4	US-09-434-122-63	Sequence 63, Appl
32	367.5	61.7	133	3	US-08-718-323A-8	Sequence 8, Appl
33	367.5	61.7	133	4	US-09-587-526-8	Sequence 8, Appl
34	366.5	61.5	118	1	US-08-491-845-14	Sequence 14, Appl
35	366.5	61.5	137	3	US-08-513-968-38	Sequence 38, Appl
36	364.5	61.2	120	3	US-09-025-769B-35	Sequence 35, Appl
37	364.5	61.2	120	3	US-09-025-769B-57	Sequence 57, Appl
38	364.5	61.2	120	4	US-09-490-070A-35	Sequence 35, Appl
39	364.5	61.2	120	4	US-09-490-070A-57	Sequence 57, Appl
40	364.5	61.2	120	4	US-09-490-153-35	Sequence 35, Appl
41	364.5	61.2	120	4	US-09-490-153-57	Sequence 37, Appl
42	364.5	61.2	120	4	US-09-490-324-35	Sequence 35, Appl
43	364.5	61.2	120	4	US-09-490-324-57	Sequence 57, Appl
44	363	60.9	123	2	US-08-561-521-11	Sequence 11, Appl
45	363	60.9	123	5	PCT-US95-01219-11	Sequence 11, Appl

#### ALIGNMENTS

RESULT 1  
US-09-025-769B-36  
Sequence 36, Application US/09025769B  
Patent No. 6300064  
GENERAL INFORMATION:  
APPLICANT: Knappik, Achim  
APPLICANT: Knappik, Peter  
APPLICANT: Illag, Vic  
APPLICANT: Ge, Liming  
APPLICANT: Moroney, Simon  
APPLICANT: Plueckchun, Andreas  
TITLE OF INVENTION: Protein/(Poly)peptide libraries  
NUMBER OF SEQUENCES: 373  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave  
STREET: 1251 Avenue of the Americas  
CITY: New York  
STATE: New York  
COUNTRY: USA  
ZIP: 10021  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/025,769B  
FILING DATE: 18-FEB-1998  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER: EP 95 11 3021.0  
FILING DATE: 18-AUG-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: James F. Haley, Jr., Esq.  
REGISTRATION NUMBER: 27,794  
REFERENCE/DOCKET NUMBER: MORPHO/5  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (212)596-9000  
TELEFAX: (212)596-9090  
INFORMATION FOR SEQ ID NO: 36:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 120 amino acids  
TYPE: amino acid  
STRANDEDNESS:  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-09-025-769B-36  
Query Match 66.5%; Score 396.5; DB 3; Length 120;  
Best local Similarity 64.2%; Pred. No. 1.8e-33;  
Matches 77; Conservative 14; Mismatches 22; Indels 7; Gaps 2;



White & McAlliff  
STREET: 1666 K Street, N.W., Suite 300  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20006  
COMPUTER READABLE FORM:  
MEDIUM TYPE: floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/490,070A  
FILING DATE: 24-Jan-2000  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: EP 95 11 3021.0  
FILING DATE: 18-AUG-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Colin G. Sandercock, Esq.  
REGISTRATION NUMBER: 31,298  
REFERENCE/DOCKET NUMBER: 37629-0005  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202) 912-2000  
TELEFAX: (202) 912-2020  
INFORMATION FOR SEQ ID NO: 59:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 120 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 59:  
US-09-490-070A-59

Query Match 66.5%; Score 396.5; DB 4; Length 120;  
Best Local Similarity 64.2%; Pred. No. 1.8e-33;  
Matches 77; Conservative 14; Mismatches 22; Indels 7; Gaps 2;

QY 1 VOLLESGAEVYKRGASVITISCONSRODFSGQYIHWYRQAPGQGFEMWGIINSGGSANY 60  
DB 2 VOLV-QSGAEVYKRGASVYKSCASGYTFTSYMHVYRQAPGQGLEWGMGINPSGSGTNY 60  
QY 61 APKFKGLTMSRDSSTDTVYMTLTSLTSEPTAVYYCL-----LQALKHMGQGLTVASS 114  
DB 61 AQKFGQVYMTTRDTISTAYMELSLRSEPTAVYYCARWGSDGFYANDYMGQGLTVASS 120

RESULT 5  
US-09-490-153-36  
Sequence 36, Application US/09490153  
Patent No. 6706484  
GENERAL INFORMATION:  
APPLICANT: Knappik, Achim  
Pack, Peter  
Ilag, Vic  
Ge, Liming  
Moroney, Simon  
Plueckhuhn, Andreas  
TITLE OF INVENTION: Protein/(Poly)peptide libraries  
NUMBER OF SEQUENCES: 373  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave  
STREET: 1251 Avenue of the Americas  
CITY: New York  
STATE: New York  
COUNTRY: USA  
ZIP: 10021  
COMPUTER READABLE FORM:  
MEDIUM TYPE: floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/490,153

FILING DATE: 24-Jan-2000  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/09/025,769B  
FILING DATE: 18-FEB-1998  
APPLICATION NUMBER: EP 95 11 3021.0  
FILING DATE: 18-AUG-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: James F. Haley, Jr., Esq.  
REGISTRATION NUMBER: 27,794  
REFERENCE/DOCKET NUMBER: MORPHO/5  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (212) 596-9000  
TELEFAX: (212) 596-9090  
INFORMATION FOR SEQ ID NO: 36:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 120 amino acids  
TYPE: amino acid  
STRANDEDNESS: <Unknown>  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 36:  
US-09-490-153-36

Query Match 66.5%; Score 396.5; DB 4; Length 120;  
Best Local Similarity 64.2%; Pred. No. 1.8e-33;  
Matches 77; Conservative 14; Mismatches 22; Indels 7; Gaps 2;

QY 1 VOLLESGAEVYKRGASVITISCONSRODFSGQYIHWYRQAPGQGFEMWGIINSGGSANY 60  
DB 2 VOLV-QSGAEVYKRGASVYKSCASGYTFTSYMHVYRQAPGQGLEWGMGINPSGSGTNY 60  
QY 61 APKFKGLTMSRDSSTDTVYMTLTSLTSEPTAVYYCL-----LQALKHMGQGLTVASS 114  
DB 61 AQKFGQVYMTTRDTISTAYMELSLRSEPTAVYYCARWGSDGFYANDYMGQGLTVASS 120

RESULT 6  
US-09-490-153-59  
Sequence 59, Application US/09490153  
Patent No. 6706484  
GENERAL INFORMATION:  
APPLICANT: Knappik, Achim  
Pack, Peter  
Ilag, Vic  
Ge, Liming  
Moroney, Simon  
Plueckhuhn, Andreas  
TITLE OF INVENTION: Protein/(Poly)peptide libraries  
NUMBER OF SEQUENCES: 373  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave  
STREET: 1251 Avenue of the Americas  
CITY: New York  
STATE: New York  
COUNTRY: USA  
ZIP: 10021  
COMPUTER READABLE FORM:  
MEDIUM TYPE: floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/490,153  
FILING DATE: 24-Jan-2000  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/09/025,769B  
FILING DATE: 18-FEB-1998  
APPLICATION NUMBER: EP 95 11 3021.0  
FILING DATE: 18-AUG-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: James F. Haley, Jr., Esq.  
REGISTRATION NUMBER: 27,794  
REFERENCE/DOCKET NUMBER: MORPHO/5

```

1 TELECOMMUNICATION INFORMATION:
2 TELEPHONE: (212)596-9000
3 TELEFAX: (212)596-9090
4 INFORMATION FOR SEQ ID NO: 59:
5 SEQUENCE CHARACTERISTICS:
6 LENGTH: 120 amino acids
7 TYPE: amino acid
8 TOPOLOGY: linear
9 MOLECULE TYPE: protein
10 SEQUENCE DESCRIPTION: SEQ ID NO: 59:
11 US-09-490-153-59
12
13 Query Match 66.5%; Score 396.5; DB 4; Length 120:
14 Best Local Similarity 64.2%; Pred. No. 1.8e-33;
15 Matches 77; Conservative 14; Mismatches 22; Indels 7; Gaps 2;
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1
```

```

US-09-490-324-36
Query Match      66.5%; Score 396.5; DB 4; Length 120;
Best Local Similarity 64.2%; Pred. No. 1.8e-33;
Matches 77; Conservative 14; Mismatches 22; Indels 7; Gaps 2;

Qy      1 VOLLEGGAEVKKRPGASVTISCOASRODFSGQYIHWVROAPGCGFEWVGIIINPSGGSANY 60
Db      2 VOLV-QSGAEVKKRPGASVTKSCKASGYTFPSYHWHVROAPGCGLEWVGIIINPSGCGTNY 60
        61 APKKRGVLMSRSDSTDTVYMTLTSLSEPTAVYYCL-----LQALKHMGCGTLVAVSS 114
        61 AAKFGKGVMTDRTISTAYMELSLKSEPTAVYYCARMGGDGFYADYMGQGLTVAVSS 120

RESULT 8
US-09-490-324-59
Sequence 59, Application US/09490324
Patent No. 6828422
GENERAL INFORMATION:
APPLICANT: Knappik, Achim
Pack, Peter
Ilag, Vic
Ge, Liming
Moroney, Simon
Plueckhuhn, Andreas
TITLE OF INVENTION: Protein/(Poly)peptide libraries
NUMBER OF SEQUENCES: 373
CORRESPONDENCE ADDRESS:
ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
STREET: 1251 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10021
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/490,324
FILING DATE: 24-Jan-2000
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/025,769
FILING DATE: 18-FEB-1998
APPLICATION NUMBER: EP 95 11 3021.0
FILING DATE: 18-AUG-1995
ATTORNEY/AGENT INFORMATION:
NAME: James F. Haley, Jr., Esq.
REGISTRATION NUMBER: 27,794
REFERENCE/DOCKET NUMBER: MORPHO/5
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)596-9000
TELEFAX: (212)596-9090
INFORMATION FOR SEQ ID NO: 59:
SEQUENCE CHARACTERISTICS:
LENGTH: 120 amino acids
TYPE: amino acid
TOPOLGY: linear
MOLECULE TYPE: protein
SEQUENCE DESCRIPTION: SEQ ID NO: 59:
US-09-490-324-59
Query Match      66.5%; Score 396.5; DB 4; Length 120;
Best Local Similarity 64.2%; Pred. No. 1.8e-33;
Matches 77; Conservative 14; Mismatches 22; Indels 7; Gaps 2;

Qy      1 VOLLEGGAEVKKRPGASVTISCOASRODFSGQYIHWVROAPGCGFEWVGIIINPSGGSANY 60
Db      2 VOLV-QSGAEVKKRPGASVTKSCKASGYTFPSYHWHVROAPGCGLEWVGIIINPSGCGTNY 60
        61 APKKRGVLMSRSDSTDTVYMTLTSLSEPTAVYYCL-----LQALKHMGCGTLVAVSS 114
        61 AAKFGKGVMTDRTISTAYMELSLKSEPTAVYYCARMGGDGFYADYMGQGLTVAVSS 120

```



Db 61 AOKFGARVTMTTRDISISITAYMELSLRSEDITAVYYCARGMGDGFYAMDMYMGQGLTVYSS 120

RESULT 9  
US-08-477-877B-94  
; Sequence 94, Application US/08477877B  
; Patent No. 5730979  
; GENERAL INFORMATION:  
; APPLICANT: Bazin, Herv  
; APPLICANT: Latine, Dominique  
; TITLE OF INVENTION: LO-CD2a Antibody and Uses Thereof for Inhibiting T-Cell Active  
; NUMBER OF SEQUENCES: 96  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Carella, Byrne, Bain, Gilfillan,  
; ADDRESSEE: Cecchi, Stewart & Olstein  
; STREET: 6 Becker Farm Road  
; CITY: Roseland  
; STATE: New Jersey  
; COUNTRY: U.S.A.  
; ZIP: 07068  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5 inch diskette  
; COMPUTER: IBM PS/2  
; OPERATING SYSTEM: MS-DOS  
; SOFTWARE: WordPerfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/477,877B  
; FILING DATE: 07-JUN-1995  
; CLASSIFICATION: 424  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/407,009  
; FILING DATE: 29-MAR-1995  
; APPLICATION NUMBER: 08/119,032  
; FILING DATE: 09-SEP-1993  
; APPLICATION NUMBER: 08/027,008  
; FILING DATE: 05-MAR-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Olstein, Elliot M.  
; REGISTRATION NUMBER: 24,025  
; REFERENCE/DOCKET NUMBER: 61750-146  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 201-994-1700  
; TELEFAX: 201-994-1744  
; INFORMATION FOR SEQ ID NO: 94:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 123 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: polypeptide  
; FEATURE:  
; NAME/KEY: Human Amu 5-3 heavy chain variable region.  
US-08-477-877B-94

Query Match 65.6%; Score 391; DB 1; Length 123;  
Best Local Similarity 61.0%; Pred. No. 7e-33;  
Matches 75; Conservative 16; Mismatches 22; Indels 10; Gaps 2;

Fig 33

Db 2 VOLV-QSGAEVKKRGASVKSCAKSGYTFGYMHWROAPGQGLEMMGRINPNSGGINY 60  
61 APKFKGLTMSRDSSTVTVMTLTSLTSEPTAVYYC-----LQALKHMGGQGLTVA 111  
AOKFGARVTMTTRDISISITAYMELSLRSEDITAVYYCARGMGDGFYAMDMYMGQGLTVYSS 120

QY 112 VSS 114  
121 VSS 123

RESULT 10

US-08-472-281A-94  
; Sequence 94, Application US/08472281A  
; Patent No. 5817311  
; GENERAL INFORMATION:  
; APPLICANT: Bazin, Herv  
; APPLICANT: Latine, Dominique  
; TITLE OF INVENTION: LO-CD2a Antibody and Uses Thereof for Inhibiting T-Cell Acti  
; NUMBER OF SEQUENCES: 96  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Carella, Byrne, Bain, Gilfillan,  
; ADDRESSEE: Cecchi, Stewart & Olstein  
; STREET: 6 Becker Farm Road  
; CITY: Roseland  
; STATE: New Jersey  
; COUNTRY: U.S.A.  
; ZIP: 07068  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5 inch diskette  
; COMPUTER: IBM PS/2  
; OPERATING SYSTEM: MS-DOS  
; SOFTWARE: WordPerfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/472,281A  
; FILING DATE: 07-JUN-1995  
; CLASSIFICATION: 424  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/407,009  
; FILING DATE: 29-MAR-1995  
; APPLICATION NUMBER: 08/119,032  
; FILING DATE: 09-SEP-1993  
; APPLICATION NUMBER: 08/027,008  
; FILING DATE: 05-MAR-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Olstein, Elliot M.  
; REGISTRATION NUMBER: 24,025  
; REFERENCE/DOCKET NUMBER: 61750-142  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 201-994-1700  
; TELEFAX: 201-994-1744  
; INFORMATION FOR SEQ ID NO: 94:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 123 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: polypeptide  
; FEATURE:  
; NAME/KEY: Human Amu 5-3 heavy chain variable region.  
US-08-472-281A-94

Query Match 65.6%; Score 391; DB 2; Length 123;  
Best Local Similarity 61.0%; Pred. No. 7e-33;  
Matches 75; Conservative 16; Mismatches 22; Indels 10; Gaps 2;

Db 2 VOLV-QSGAEVKKRGASVKSCAKSGYTFGYMHWROAPGQGLEMMGRINPNSGGINY 60  
61 APKFKGLTMSRDSSTVTVMTLTSLTSEPTAVYYC-----LQALKHMGGQGLTVA 111  
AOKFGARVTMTTRDISISITAYMELSLRSEDITAVYYCARGMGDGFYAMDMYMGQGLTVYSS 120

QY 112 VSS 114  
121 VSS 123

RESULT 11

US-08-477-989B-94  
; Sequence 94, Application US/08477989B  
; Patent No. 5951983  
; GENERAL INFORMATION:  
; APPLICANT: Bazin, Herv

```
; APPLICANT: Latime, Dominique
; APPLICANT: Kaplan, Ruth
; APPLICANT: Kieber-Emmons, Thomas
; APPLICANT: Postema, Christina E.
; APPLICANT: White-Scharf, Mary
; TITLE OF INVENTION: LO-CD2a Antibody and Uses
; TITLE OF INVENTION: Theresof for Inhibiting
; TITLE OF INVENTION: T-Cell Activation and
; TITLE OF INVENTION: Proliferation
; NUMBER OF SEQUENCES: 96
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Carella, Byrne, Bain, Gilfillan,
; STREET: 6 Becker Farm Road
; CITY: Roseland
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07068
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch diskette
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/477,989B
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/407,009
; FILING DATE: 29-MAR-1995
; APPLICATION NUMBER: 08/119,032
; FILING DATE: 09-SEP-1993
; APPLICATION NUMBER: 08/027,008
; FILING DATE: 05-MAR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Olstein, Elliot M.
; REGISTRATION NUMBER: 24,025
; REFERENCE/DOCKET NUMBER: 61750-147
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201-994-1700
; TELEFAX: 201-994-1744
; INFORMATION FOR SEQ ID NO: 94:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 123 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: polypeptide
; FEATURE:
; NAME/KEY: Human Amu 5-3 heavy chain variable
; NAME/KEY: region.
US-08-477-989B-94

Query Match      65.6%; Score 391; DB 2; Length 123;
Best Local Similarity 61.0%; Pred. No. 7e-33;
Matches 75; Conservative 16; Mismatches 22; Indels 10; Gaps 2;
```

```
; Patent No. 6300064
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 117 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-025-769B-22

Query Match      65.3%; Score 389; DB 3; Length 117;
Best Local Similarity 64.1%; Pred. No. 1.1e-32;
Matches 75; Conservative 15; Mismatches 23; Indels 4; Gaps 2;
```

```
QY      1 VOLLEQSGAEVKKRPGASVTTISCOASRODPSGOYIHWVROAPGCGFEMGIIINPSGGSANY 60
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      2 VOLV-QSGAEVKKRPGASVSVCKASGYTFTSYMHVROAPGCGLEMMGMINPSGGSNTY 60
QY      61 APRFKGLTMSRDSSTDTIVYMTLTSLTSEDVAVYCYLQ--ALKHWGGTVAVSS 114
      |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
Db      61 AQFGQRYVMTSDTISTAYMELSLRSDTAIVYCCARDGDFYWGCGTLVTVSS 117

RESULT 13
US-09-490-070A-22
; Sequence 22, Application US/09490070A
; Patent No. 6696248
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
; White & McAlliff
```

STREET: 1666 K Street, N.W., Suite 300  
City: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20006  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)  
CURRENT APPLICATION DATA:  
FILING DATE: 24-Jan-2000  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER: EP 95 11 3021.0  
FILING DATE: 18-AUG-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Colin G. Sandercock, Esq.  
REGISTRATION NUMBER: 31,298  
REFERENCE/DOCKET NUMBER: 37629-0005  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202) 912-2000  
TELEFAX: (202) 912-2020  
INFORMATION FOR SEQ ID NO: 22:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 117 amino acids  
TYPE: amino acid  
STRANDEDNESS: <Unknown>  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 22:  
US-09-490-070A-22

Query Match 65.3%; Score 389; DB 4; Length 117;  
Best Local Similarity 64.1%; Pred. No. 1.1e-32;  
Matches 75; Conservative 15; Mismatches 23; Indels 4; Gaps 2;

QY 1 VOLLEQSGAEVKKRPGASVITSCQASRODFSGQYIHVWRQAPGQGFEMMGIIINSGGSANY 60  
DB 2 VOLV-QSGAEVKKRPGASVITSCQASGYTFTSYMHVWRQAPGQGLEMMGWINNSGNTNY 60

QY 61 APFKGRILMSRDSSTDTVYMTLTSLTSEPTAVYYCLQ--ALKHWGGTIVAVSS 114  
DB 61 AQKFGQRYVMTRTDSTISTAYMELSLRSDDTAVYYCARDDGGGFDYWGQGLTVTVSS 117

RESULT 14  
US-09-490-153-22  
Sequence 22, Application US/09490153  
Patent No. 6706484  
GENERAL INFORMATION:  
APPLICANT: Knappik, Achim  
Pack, Peter  
Ilag, Vic  
Ge, Liming  
Moroney, Simon  
Plueckhuhn, Andreas  
TITLE OF INVENTION: Protein/(Poly)peptide libraries  
NUMBER OF SEQUENCES: 373  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave  
STREET: 1251 Avenue of the Americas  
CITY: New York  
STATE: New York  
COUNTRY: USA  
ZIP: 10021  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/490,153

FILING DATE: 24-Jan-2000  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/09/025,769B  
FILING DATE: 18-FEB-1998  
APPLICATION NUMBER: EP 95 11 3021.0  
FILING DATE: 18-AUG-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: James F. Haley, Jr., Esq.  
REGISTRATION NUMBER: 27,794  
REFERENCE/DOCKET NUMBER: MORPHO/5  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (212) 596-9000  
TELEFAX: (212) 596-9090  
INFORMATION FOR SEQ ID NO: 22:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 117 amino acids  
TYPE: amino acid  
STRANDEDNESS: <Unknown>  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 22:  
US-09-490-153-22

Query Match 65.3%; Score 389; DB 4; Length 117;  
Best Local Similarity 64.1%; Pred. No. 1.1e-32;  
Matches 75; Conservative 15; Mismatches 23; Indels 4; Gaps 2;

QY 1 VOLLEQSGAEVKKRPGASVITSCQASRODFSGQYIHVWRQAPGQGFEMMGIIINSGGSANY 60  
DB 2 VOLV-QSGAEVKKRPGASVITSCQASGYTFTSYMHVWRQAPGQGLEMMGWINNSGNTNY 60

QY 61 APFKGRILMSRDSSTDTVYMTLTSLTSEPTAVYYCLQ--ALKHWGGTIVAVSS 114  
DB 61 AQKFGQRYVMTRTDSTISTAYMELSLRSDDTAVYYCARDDGGGFDYWGQGLTVTVSS 117

RESULT 15  
US-09-490-324-22  
Sequence 22, Application US/09490324  
Patent No. 6828422  
GENERAL INFORMATION:  
APPLICANT: Knappik, Achim  
Pack, Peter  
Ilag, Vic  
Ge, Liming  
Moroney, Simon  
Plueckhuhn, Andreas  
TITLE OF INVENTION: Protein/(Poly)peptide libraries  
NUMBER OF SEQUENCES: 373  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave  
STREET: 1251 Avenue of the Americas  
CITY: New York  
STATE: New York  
COUNTRY: USA  
ZIP: 10021  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)  
CURRENT APPLICATION DATA:  
FILING DATE: 24-Jan-2000  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER: US/09/025,769  
FILING DATE: 18-FEB-1998  
APPLICATION NUMBER: EP 95 11 3021.0  
FILING DATE: 18-AUG-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: James F. Haley, Jr., Esq.  
REGISTRATION NUMBER: 27,794  
REFERENCE/DOCKET NUMBER: MORPHO/5

```

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 596-9000
; TELEFAX: (212) 596-9090
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 117 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 22:
US-09-490-324-22

Query Match 65.3%; Score 389; DB 4; Length 117;
Best Local Similarity 64.1%; Pred. No. 1.1e-32; Indels 4; Gaps 2;
Matches 75; Conservative 15; Mismatches 23;

QY 1 VQLLEQSGAEVKKRPGASVTISCOASRODPSGQYIHVYRQAPGQGFEMWGIINPSGGSANY 60
Db 2 VQLV-QSGAEVKKRPGASVVKSCASGYTFISYMHVYRQAPGQGFEMWGIINPSGNTNY 60
QY 61 APEFKGRLLTMSRDSSTDTVTMTLTLTSEPTAVYYCLQ--ALKHWGGTLVAVSS 114
Db 61 AQKFGGRVMTWTRDTSISTAYMELSLRSDDTAVYYCARDDGGGFDYWGQGTIVTVSS 117
```

Search completed: November 9, 2005, 06:00:21  
Job time: 24 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

# OM protein - protein search, using sw model

Run on: November 9, 2005, 05:52:18 ; Search time 166 Seconds  
(without alignments)  
265.607 Million cell updates/sec

Title: US-09-936-964A-36

Perfect score: 1 VQLLEQSGAEVKRPGASVTI.....YCLQLQKHWGQGLTAVVSS 114

Sequence: 1 VQLLEQSGAEVKRPGASVTI.....YCLQLQKHWGQGLTAVVSS 114

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%

Database : A\_Geneseq\_16Dec04:\*  
Listing first 45 summaries

1: geneseqp19808:\*  
2: geneseqp19908:\*  
3: geneseqp20008:\*  
4: geneseqp20018:\*  
5: geneseqp20028:\*  
6: geneseqp20038:\*  
7: geneseqp20039:\*  
8: geneseqp20048:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	596	100.0	114	3	AA18864 Amino aci
2	596	100.0	114	3	AA18860 Amino aci
3	596	100.0	114	3	AA18876 Amino aci
4	596	100.0	114	3	AA18862 Amino aci
5	596	100.0	114	3	AA18866 Amino aci
6	590	99.0	114	3	AA18868 Amino aci
7	588	98.7	114	3	AA18858 Amino aci
8	578	97.0	114	3	AA18874 Amino aci
9	564	94.6	114	3	AA18882 Amino aci
10	536	89.9	114	3	AA18880 Amino aci
11	536	89.9	114	3	AA18878 Amino aci
12	536	89.9	114	3	AA18870 Amino aci
13	536	89.9	114	3	AA18856 Amino aci
14	536	89.9	114	3	AA18872 Amino aci
15	421	70.6	124	3	AA18872 Amino aci
16	419.5	70.4	124	3	AA18872 Amino aci
17	418	70.1	142	6	AD47344 Human ant
18	418	70.1	142	6	AD47344 Human ant
19	418	70.1	142	6	AD47344 Human ant
20	418	70.1	142	6	AD47344 Human ant
21	414	69.5	255	5	AD47344 Human ant
22	414	69.5	255	5	AD47344 Human ant
23	413.5	69.4	245	7	AD47344 Human ant
24	413.5	69.4	245	7	AD47344 Human ant
25	412	69.1	117	8	AD47344 Human ant

26	412	69.1	117	8	AD47344 Human ant
27	412	69.1	249	8	AD47344 Human ant
28	412	69.1	249	8	AD47344 Human ant
29	411.5	69.0	241	7	AD47344 Human ant
30	410	68.8	248	5	AD47344 Human ant
31	410	68.8	248	5	AD47344 Human ant
32	409	68.6	248	5	AD47344 Human ant
33	409	68.6	248	5	AD47344 Human ant
34	408.5	68.5	125	5	AD47344 Human ant
35	408.5	68.5	249	5	AD47344 Human ant
36	408.5	68.5	249	5	AD47344 Human ant
37	408.5	68.5	249	5	AD47344 Human ant
38	408.5	68.5	249	5	AD47344 Human ant
39	408.5	68.5	251	5	AD47344 Human ant
40	408.5	68.5	251	5	AD47344 Human ant
41	408.5	68.5	254	5	AD47344 Human ant
42	408.5	68.5	254	5	AD47344 Human ant
43	407.5	68.4	114	7	AD47344 Human ant
44	407	68.3	258	5	AD47344 Human ant
45	407	68.3	258	5	AD47344 Human ant

## ALIGNMENTS

RESULT 1	AA18864 standard; protein; 114 AA.
ID	AA18864
AC	AA18864;
DT	08-FEB-2001 (first entry)
DE	Amino acid sequence of anti-p53 antibody heavy chain clone 163.7.
XX	p53: antibody; immune response; vaccine; gene therapy; cancer;
KW	rheumatoid arthritis; coronary heart disease.
OS	Homo sapiens.
XX	WO200056770-A1.
PN	28-SEP-2000.
PD	15-MAR-2000; 2000WC-AU000189.
XX	19-MAR-1999; 99AU-00009321.
PR	(SVIN-) ST VINCENT'S HOSPITAL SYDNEY LTD.
PA	Ward RL, Coomber DMU;
PI	WPL: 2000-638249/61.
XX	N-PSDB; AAA6141.
DR	Polynucleotides encoding anti-p53 antibodies, polypeptides and peptide
XX	fragments, useful in treatment and diagnosis of cancer, rheumatoid
PT	arthritis and coronary heart disease.
XX	Claim 30; Page 139; 163pp; English.
XX	The present sequence represents the heavy chain of an antibody reactive
CC	against p53. The antibody is obtained from a vertebrate host expressing
CC	an immune response against a naturally occurring disease. The antibodies
CC	are useful in pharmaceutical compositions, which additionally contain
CC	chelators, drugs, produgs, toxins and imaging markers e.g. radioisotopes
CC	or gadolinium. The polypeptide components of the antibodies are useful in
CC	vaccines, for inducing an immune response against a disease and for detection
CC	vertebrate, for treatment and/or prophylaxis of disease and for detection
CC	purposes. The nucleic acid sequences can be used to detect a disease as
CC	well as for gene therapy and recombinant production of the polypeptides.
CC	In particular, the following can be treated cancer, rheumatoid arthritis
CC	and coronary heart disease. Cancers include carcinogenic tumours, tumours

CC of epithelial origin, e.g. colo-rectal cancer, breast cancer lung cancer,  
CC head and neck tumours, hepatic cancer, pancreatic cancer, ovarian cancer,  
CC gastric cancer, brain cancer, bladder cancer, prostate cancer and  
CC urinary/genital tract cancer, oesophageal cancer, mesenchymal tumours,  
CC e.g. sarcoma, and hemopoietic tumours, e.g. B cell lymphoma  
XX  
SQ Sequence 114 AA;

Query Match 100.0%; Score 596; DB 3; Length 114;  
Best Local Similarity 100.0%; Pred. No. 1,1e-46;  
Matches 114; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VQLLESGAEVKRPGASVTISCOASRDPSGQYIHVWRQAPQGPFMMGIINPSGGSANY 60  
Db 1 VQLLESGAEVKRPGASVTISCOASRDPSGQYIHVWRQAPQGPFMMGIINPSGGSANY 60

QY 61 APEFKGRLTMSRDSSTDYVMTLTSLTSEDTAVVYCLLQALHKGWGCTLVAVSS 114  
Db 61 APEFKGRLTMSRDSSTDYVMTLTSLTSEDTAVVYCLLQALHKGWGCTLVAVSS 114

## RESULT 2

AAB18860  
ID AAB18860 standard; protein; 114 AA.

XX AAB18860;

DT 08-FEB-2001 (first entry)

DE Amino acid sequence of anti-p53 antibody heavy chain clone 163.5.

XX p53; antibody; immune response; vaccine; gene therapy; cancer;

KM rheumatoid arthritis; coronary heart disease.

XX Homo sapiens.

OS MO200056770-A1.

XX 28-SEP-2000.

PF 15-MAR-2000; 2000MO-AU000189.

PR 19-MAR-1999; 99AU-00009321.

XX (SVIN-) ST VINCENT'S HOSPITAL SYDNEY LTD.

PI Ward RL, Coomber DWJ;

XX WPI; 2000-638249/61.

DR N-PSDB; AAA96137.

PT Polynucleotides encoding anti-p53 antibodies, polypeptides and peptide  
PT fragments, useful in treatment and diagnosis of cancer, rheumatoid  
PT arthritis and coronary heart disease.

XX Claim 30; Page 135; 163pp; English.

XX The present sequence represents the heavy chain of an antibody reactive  
CC against p53. The antibody is obtained from a vertebrate host expressing  
CC an immune response against a naturally occurring disease. The antibodies  
CC are useful in pharmaceutical compositions, which additionally contain  
CC chelators, drugs, produgs, toxins and imaging markers e.g. radioisotopes  
CC or gadolinium. The polypeptide components of the antibodies are useful in  
CC vaccines, for inducing an immune response against a disease in a  
CC vertebrate, for treatment and/or prophylaxis of disease and for detection  
CC purposes. The nucleic acid sequences can be used to detect a disease as  
CC well as for gene therapy and recombinant production of the polypeptides.  
CC In particular, the following can be treated cancer, rheumatoid arthritis  
CC and coronary heart disease. Cancers include carcinogenic tumours, tumours  
CC of epithelial origin, e.g. colo-rectal cancer, breast cancer lung cancer,  
CC head and neck tumours, hepatic cancer, pancreatic cancer, ovarian cancer,  
CC gastric cancer, brain cancer, bladder cancer, prostate cancer and  
CC urinary/genital tract cancer, oesophageal cancer, mesenchymal tumours,

CC e.g. sarcoma, and hemopoietic tumours, e.g. B cell lymphoma  
XX  
SQ Sequence 114 AA;

Query Match 100.0%; Score 596; DB 3; Length 114;  
Best Local Similarity 100.0%; Pred. No. 1,1e-46;  
Matches 114; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VQLLESGAEVKRPGASVTISCOASRDPSGQYIHVWRQAPQGPFMMGIINPSGGSANY 60  
Db 1 VQLLESGAEVKRPGASVTISCOASRDPSGQYIHVWRQAPQGPFMMGIINPSGGSANY 60

QY 61 APEFKGRLTMSRDSSTDYVMTLTSLTSEDTAVVYCLLQALHKGWGCTLVAVSS 114  
Db 61 APEFKGRLTMSRDSSTDYVMTLTSLTSEDTAVVYCLLQALHKGWGCTLVAVSS 114

## RESULT 3

AAB18876  
ID AAB18876 standard; protein; 114 AA.

XX AAB18876;

DT 08-FEB-2001 (first entry)

DE Amino acid sequence of anti-p53 antibody heavy chain clone 163.20.

XX p53; antibody; immune response; vaccine; gene therapy; cancer;

KM rheumatoid arthritis; coronary heart disease.

XX Homo sapiens.

PN MO200056770-A1.

XX 28-SEP-2000.

PF 15-MAR-2000; 2000MO-AU000189.

PR 19-MAR-1999; 99AU-00009321.

XX (SVIN-) ST VINCENT'S HOSPITAL SYDNEY LTD.

PI Ward RL, Coomber DWJ;

XX WPI; 2000-638249/61.

DR N-PSDB; AAA96153.

PT Polynucleotides encoding anti-p53 antibodies, polypeptides and peptide  
PT fragments, useful in treatment and diagnosis of cancer, rheumatoid  
PT arthritis and coronary heart disease.

XX Claim 30; Page 151; 163pp; English.

XX The present sequence represents the heavy chain of an antibody reactive  
CC against p53. The antibody is obtained from a vertebrate host expressing  
CC an immune response against a naturally occurring disease. The antibodies  
CC are useful in pharmaceutical compositions, which additionally contain  
CC chelators, drugs, produgs, toxins and imaging markers e.g. radioisotopes  
CC or gadolinium. The polypeptide components of the antibodies are useful in  
CC vaccines, for inducing an immune response against a disease in a  
CC vertebrate, for treatment and/or prophylaxis of disease and for detection  
CC purposes. The nucleic acid sequences can be used to detect a disease as  
CC well as for gene therapy and recombinant production of the polypeptides.  
CC In particular, the following can be treated cancer, rheumatoid arthritis  
CC and coronary heart disease. Cancers include carcinogenic tumours, tumours  
CC of epithelial origin, e.g. colo-rectal cancer, breast cancer lung cancer,  
CC head and neck tumours, hepatic cancer, pancreatic cancer, ovarian cancer,  
CC gastric cancer, brain cancer, bladder cancer, prostate cancer, and  
CC urinary/genital tract cancer, oesophageal cancer, mesenchymal tumours,  
CC e.g. sarcoma, and hemopoietic tumours, e.g. B cell lymphoma  
XX  
SQ Sequence 114 AA;

Query Match 100.0%; Score 596; DB 3; Length 114;  
Best Local Similarity 100.0%; Pred. No. 1.1e-46;  
Matches 114; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VOLLEQSGAEVYKRPQASVTISCOASRODPFSGQYIHWVROAPQGFEMWGIINPSCGSANY 60  
DB 1 VOLLEQSGAEVYKRPQASVTISCOASRODPFSGQYIHWVROAPQGFEMWGIINPSCGSANY 60

QY 61 APKFKGRITMSRDSSTDTVYMTLTSLTSEDTAVYVYCLLQALKHMGQGLTAVSS 114  
DB 61 APKFKGRITMSRDSSTDTVYMTLTSLTSEDTAVYVYCLLQALKHMGQGLTAVSS 114

RESULT 4  
AAB18862  
ID AAB18862 standard; protein; 114 AA.  
XX AAB18862;  
AC  
XX 08-FEB-2001 (first entry)  
DT  
XX Amino acid sequence of anti-p53 antibody heavy chain clone 163.6.  
DE  
XX p53; antibody; immune response; vaccine; gene therapy; cancer;  
KM rheumatoid arthritis; coronary heart disease.  
KW  
XX Homo sapiens.  
OS  
XX MO200056770-A1.  
PN  
XX 28-SEP-2000.  
PD  
XX 15-MAR-2000; 2000MO-AU000189.  
PF  
XX 19-MAR-1999; 99AU-00009321.  
PR  
XX (SVIN-) ST VINCENT'S HOSPITAL SYDNEY LTD.  
PA  
XX Ward RL, Coomber DMJ;  
PI  
XX WPI: 2000-638249/61.  
DR N-PSDB; AAA96139.  
XX

PT Polynucleotides encoding anti-p53 antibodies, polypeptides and peptide  
PT fragments, useful in treatment and diagnosis of cancer, rheumatoid  
PT arthritis and coronary heart disease.  
XX

PS Claim 30; Page 137; 163pp; English.

CC The present sequence represents the heavy chain of an antibody reactive  
CC against p53. The antibody is obtained from a vertebrate host expressing  
CC an immune response against a naturally occurring disease. The antibodies  
CC are useful in pharmaceutical compositions, which additionally contain  
CC chelators, drugs, produgs, toxins and imaging markers e.g. radioisotopes  
CC or gadolinium. The polypeptide components of the antibodies are useful in  
CC vaccines, for inducing an immune response against a disease in a  
CC vertebrate, for treatment and/or prophylaxis of disease and for detection  
CC purposes. The nucleic acid sequences can be used to detect a disease as  
CC well as for gene therapy and recombinant production of the polypeptides.  
CC In particular, the following can be treated cancer, rheumatoid arthritis  
CC and coronary heart disease. Cancers include carcinogenic tumours, tumours  
CC of epithelial origin, e.g. colo-rectal cancer, breast cancer lung cancer,  
CC head and neck tumours, hepatic cancer, pancreatic cancer, ovarian cancer,  
CC gastric cancer, brain cancer, bladder cancer, prostate cancer and  
CC urinary/genital tract cancer, oesophageal cancer, mesenchymal tumours,  
CC e.g. sarcoma, and hemopoietic tumours, e.g. B cell lymphoma  
XX

XX Sequence 114 AA;

Query Match 100.0%; Score 596; DB 3; Length 114;  
Best Local Similarity 100.0%; Pred. No. 1.1e-46;  
Matches 114; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VOLLEQSGAEVYKRPQASVTISCOASRODPFSGQYIHWVROAPQGFEMWGIINPSCGSANY 60  
DB 1 VOLLEQSGAEVYKRPQASVTISCOASRODPFSGQYIHWVROAPQGFEMWGIINPSCGSANY 60

QY 61 APKFKGRITMSRDSSTDTVYMTLTSLTSEDTAVYVYCLLQALKHMGQGLTAVSS 114  
DB 61 APKFKGRITMSRDSSTDTVYMTLTSLTSEDTAVYVYCLLQALKHMGQGLTAVSS 114

RESULT 5  
AAB18866  
ID AAB18866 standard; protein; 114 AA.  
XX AAB18866;  
AC  
XX 08-FEB-2001 (first entry)  
DT  
XX Amino acid sequence of anti-p53 antibody heavy chain clone 163.9.  
DE  
XX p53; antibody; immune response; vaccine; gene therapy; cancer;  
KM rheumatoid arthritis; coronary heart disease.  
KW  
XX Homo sapiens.  
OS  
XX MO200056770-A1.  
PN  
XX 28-SEP-2000.  
PD  
XX 15-MAR-2000; 2000MO-AU000189.  
PF  
XX 19-MAR-1999; 99AU-00009321.  
PR  
XX (SVIN-) ST VINCENT'S HOSPITAL SYDNEY LTD.  
PA  
XX Ward RL, Coomber DMJ;  
PI  
XX WPI: 2000-638249/61.  
DR N-PSDB; AAA96143.  
XX

PT Polynucleotides encoding anti-p53 antibodies, polypeptides and peptide  
PT fragments, useful in treatment and diagnosis of cancer, rheumatoid  
PT arthritis and coronary heart disease.  
XX

PS Claim 30; Page 141; 163pp; English.

CC The present sequence represents the heavy chain of an antibody reactive  
CC against p53. The antibody is obtained from a vertebrate host expressing  
CC an immune response against a naturally occurring disease. The antibodies  
CC are useful in pharmaceutical compositions, which additionally contain  
CC chelators, drugs, produgs, toxins and imaging markers e.g. radioisotopes  
CC or gadolinium. The polypeptide components of the antibodies are useful in  
CC vaccines, for inducing an immune response against a disease in a  
CC vertebrate, for treatment and/or prophylaxis of disease and for detection  
CC purposes. The nucleic acid sequences can be used to detect a disease as  
CC well as for gene therapy and recombinant production of the polypeptides.  
CC In particular, the following can be treated cancer, rheumatoid arthritis  
CC and coronary heart disease. Cancers include carcinogenic tumours, tumours  
CC of epithelial origin, e.g. colo-rectal cancer, breast cancer lung cancer,  
CC head and neck tumours, hepatic cancer, pancreatic cancer, ovarian cancer,  
CC gastric cancer, brain cancer, bladder cancer, prostate cancer and  
CC urinary/genital tract cancer, oesophageal cancer, mesenchymal tumours,  
CC e.g. sarcoma, and hemopoietic tumours, e.g. B cell lymphoma  
XX

XX Sequence 114 AA;

Query Match 100.0%; Score 596; DB 3; Length 114;  
Best Local Similarity 100.0%; Pred. No. 1.1e-46;  
Matches 114; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 VOLLEQSGAEVYKRPQASVTISCOASRODPFSGQYIHWVROAPQGFEMWGIINPSCGSANY 60  
DB 1 VOLLEQSGAEVYKRPQASVTISCOASRODPFSGQYIHWVROAPQGFEMWGIINPSCGSANY 60





```

XX AC AAB18874;
XX DT 08-FEB-2001 (first entry)
XX DE Amino acid sequence of anti-p53 antibody heavy chain clone 163.17.
XX KM p53; antibody; immune response; vaccine; gene therapy; cancer;
XX KW rheumatoid arthritis; coronary heart disease.
XX OS Homo sapiens.
XX FH Key location/Qualifiers
XX FT Misc-difference 77 /note= "Glu encoded by GAC"
XX PN WO200056770-A1.
XX PD 28-SEP-2000.
XX PF 15-MAR-2000; 2000WO-AU000189.
XX PR 19-MAR-1999; 99AU-00009321.
XX PA (SVIN-) ST VINCENT'S HOSPITAL SYDNEY LTD.
XX PI Ward RL, Coomber DMJ;
XX DR WPI; 2000-638249/61.
XX DR N-PSDB; AAA96151.
XX PT Polynucleotides encoding anti-p53 antibodies, polypeptides and peptide
XX PT fragments, useful in treatment and diagnosis of cancer, rheumatoid
XX PT arthritis and coronary heart disease.
XX PS Claim 30; Page 149; 163pp; English.
XX CC The present sequence represents the heavy chain of an antibody reactive
XX CC against p53. The antibody is obtained from a vertebrate host expressing
XX CC an immune response against a naturally occurring disease. The antibodies
XX CC are useful in pharmaceutical compositions, which additionally contain
XX CC chelators, drugs, produgs, toxins and imaging markers e.g. radioisotopes
XX CC or gadolinium. The polypeptide components of the antibodies are useful in
XX CC vaccines, for inducing an immune response against a disease in a
XX CC vertebrate, for treatment and/or prophylaxis of disease and for detection
XX CC purposes. The nucleic acid sequences can be used to detect a disease as
XX CC well as for gene therapy and recombinant production of the polypeptides.
XX CC In particular, the following can be treated cancer, rheumatoid arthritis
XX CC and coronary heart disease. Cancers include carcinogenic tumours, tumours
XX CC of epithelial origin, e.g. colo-rectal cancer, breast cancer lung cancer,
XX CC head and neck tumours, hepatic cancer, pancreatic cancer, ovarian cancer,
XX CC gastric cancer, brain cancer, bladder cancer, prostate cancer and
XX CC urinary/genital tract cancer, oesophageal cancer, mesenchymal tumours,
XX CC e.g. sarcoma, and hemopoietic tumours, e.g. B cell lymphoma
XX SQ Sequence 114 AA;
XX
Query Match 97.0%; Score 578; DB 3; Length 114;
Best Local Similarity 96.5%; Pred. No. 5e-45;
Matches 110; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

```

```

XX AC AAB18882;
XX DT 08-FEB-2001 (first entry)
XX DE Amino acid sequence of anti-p53 antibody heavy chain clone 163.24.
XX KM p53; antibody; immune response; vaccine; gene therapy; cancer;
XX KW rheumatoid arthritis; coronary heart disease.
XX OS Homo sapiens.
XX FH Key location/Qualifiers
XX FT Misc-difference 77 /note= "Glu encoded by GAC"
XX PN WO200056770-A1.
XX PD 28-SEP-2000.
XX PF 15-MAR-2000; 2000WO-AU000189.
XX PR 19-MAR-1999; 99AU-00009321.
XX PA (SVIN-) ST VINCENT'S HOSPITAL SYDNEY LTD.
XX PI Ward RL, Coomber DMJ;
XX DR WPI; 2000-638249/61.
XX DR N-PSDB; AAA96159.
XX PT Polynucleotides encoding anti-p53 antibodies, polypeptides and peptide
XX PT fragments, useful in treatment and diagnosis of cancer, rheumatoid
XX PT arthritis and coronary heart disease.
XX PS Claim 30; Page 157; 163pp; English.
XX CC The present sequence represents the heavy chain of an antibody reactive
XX CC against p53. The antibody is obtained from a vertebrate host expressing
XX CC an immune response against a naturally occurring disease. The antibodies
XX CC are useful in pharmaceutical compositions, which additionally contain
XX CC chelators, drugs, produgs, toxins and imaging markers e.g. radioisotopes
XX CC or gadolinium. The polypeptide components of the antibodies are useful in
XX CC vaccines, for inducing an immune response against a disease in a
XX CC vertebrate, for treatment and/or prophylaxis of disease and for detection
XX CC purposes. The nucleic acid sequences can be used to detect a disease as
XX CC well as for gene therapy and recombinant production of the polypeptides.
XX CC In particular, the following can be treated cancer, rheumatoid arthritis
XX CC and coronary heart disease. Cancers include carcinogenic tumours, tumours
XX CC of epithelial origin, e.g. colo-rectal cancer, breast cancer lung cancer,
XX CC head and neck tumours, hepatic cancer, pancreatic cancer, ovarian cancer,
XX CC gastric cancer, brain cancer, bladder cancer, prostate cancer and
XX CC urinary/genital tract cancer, oesophageal cancer, mesenchymal tumours,
XX CC e.g. sarcoma, and hemopoietic tumours, e.g. B cell lymphoma
XX SQ Sequence 114 AA;
XX
Query Match 94.6%; Score 564; DB 3; Length 114;
Best Local Similarity 93.0%; Pred. No. 9.5e-44;
Matches 106; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

```

KM	rheumatoid arthritis; coronary heart disease.
OS	Homo sapiens.
XX	
PN	MO200056770-A1.
XX	
PD	28-SEP-2000.
XX	
FF	15-MAR-2000; 2000OWO-AU000189.
XX	
PR	19-MAR-1999; 99AU-00009321.
XX	
PA	(SVIN-) ST VINCENT'S HOSPITAL SYDNEY LTD.
XX	
P1	Ward RL, Coomber DMJ;
XX	
DR	WPI; 2000-638249/61.
DR	N-PSDB; AAA96155.
XX	
PT	Polynucleotides encoding anti-p53 antibodies, polypeptides and peptide fragments, useful in treatment and diagnosis of cancer, rheumatoid arthritis and coronary heart disease.
XX	
PS	Claim 30; Page 153; 163pp; English.
XX	
CC	The present sequence represents the heavy chain of an antibody reactive against p53. The antibody is obtained from a vertebrate host expressing an immune response against a naturally occurring disease. The antibodies are useful in pharmaceutical compositions, which additionally contain chelators, drugs, produgs, toxins and imaging markers e.g. radioisotopes or gadolinium. The polypeptide components of the antibodies are useful in vaccines, for inducing an immune response against a disease in a vertebrate, for treatment and/or prophylaxis of disease and for detection purposes. The nucleic acid sequences can be used to detect a disease as well as for gene therapy and recombinant production of the polypeptides. In particular, the following can be treated cancer, rheumatoid arthritis and coronary heart disease. Cancers include carcinogenic tumours, tumours of epithelial origin, e.g. colo-rectal cancer, breast cancer lung cancer, head and neck tumours, hepatic cancer, pancreatic cancer, ovarian cancer, gastric cancer, brain cancer, bladder cancer, prostate cancer and urinary/genital tract cancer, oesophageal cancer, mesenchymal tumours, e.g. sarcoma, and hemopoietic tumours, e.g. B cell lymphoma
CC	
CC	
XX	
SQ	Sequence 114 AA;
Query Match	89.9%; Score 536; DB 3; Length 114;
Best Local Similarity	88.6%; Pred. No. 3,4e-41;
Matches 101; Conservative	8; Mismatches 5; Indels 0; Gaps 0;
QY	1 VLLLESGAEVKRPGASVITSCQASRODPFGQYIHWYRQAPGQGFEMWGIINPSGGSANY 60
DB	1 VLLLESGAEVKRPGASVITSCQASRQTFSGQYIHWYRQAPGQGLEWVGIVNPSGGSANY 60
QY	61 APRKGGITMSRPSSTDYVYMTLTSLTSEPTAVYYCCLOALKHMGQSTLVAVSS 114
DB	61 APSFGRLSWSRDASTNYVMKLSLTSEPTAVYYCCLSQALKTWGQSTLVAVSS 114
RESULT 12	
AA18870	
ID	AA18870 standard; protein; 114 AA.
XX	
AC	AA18870;
XX	
DT	08-FEB-2001 (first entry)
XX	
DE	Amino acid sequence of anti-p53 antibody heavy chain clone 163.15.
XX	
KW	p53; antibody; immune response; vaccine; gene therapy; cancer;
KW	rheumatoid arthritis; coronary heart disease.
XX	
OS	Homo sapiens
XX	

PN WO200056770-A1.  
XX 28-SEP-2000.  
XX  
XX 15-MAR-2000; 2000WO-AU000189.  
XX  
XX 19-MAR-1999; 99AU-00009321.  
XX  
XX (SVIN-) ST VINCENT'S HOSPITAL SYDNEY LTD.  
XX  
XX Ward RL, Coomber DMJ;  
XX WPI: 2000-638249/61.  
XX N-PSDB: AAA96147.  
XX  
XX  
XX Polynucleotides encoding anti-p53 antibodies, polypeptides and peptide fragments, useful in treatment and diagnosis of cancer, rheumatoid arthritis and coronary heart disease.  
XX  
XX Claim 30; Page 145; 163pp; English.  
XX  
XX The present sequence represents the heavy chain of an antibody reactive against p53. The antibody is obtained from a vertebrate host expressing an immune response against a naturally occurring disease. The antibodies are useful in pharmaceutical compositions, which additionally contain chelators, drugs, products, toxins and imaging markers e.g. radioisotopes or gadolinium. The polypeptide components of the antibodies are useful in vaccines, for inducing an immune response against a disease in a vertebrate, for treatment and/or prophylaxis of disease and for detection purposes. The nucleic acid sequences can be used to detect a disease as well as for gene therapy and recombinant production of the polypeptides. In particular, the following can be treated cancer, rheumatoid arthritis and coronary heart disease. Cancers include carcinogenic tumours, tumours of epithelial origin, e.g. colo-rectal cancer, breast cancer lung cancer, head and neck tumours, hepatic cancer, pancreatic cancer, ovarian cancer, gastric cancer, brain cancer, bladder cancer, prostate cancer and urinary/genital tract cancer, oesophageal cancer, mesenchymal tumours, e.g. sarcoma, and hemopoietic tumours, e.g. B cell lymphoma  
XX  
XX Sequence 114 AA;  
SQ  
Query Match 89.9%; Score 536; DB 3; Length 114;  
Best Local Similarity 88.6%; Pred. No. 3.4e-41;  
Matches 101; Conservative 8; Mismatches 5; Indels 0; Gaps 0;  
QY 1 VOLLESGAEVKGKPGASVTISCOASRODFSGQYIHWVROAPGCGFEMWGIINPGSGSANY 60  
DB 1 VOLLESGAEVKGKPGASVTISCOASROTFSGQYIHWVROAPGCGLEMMGVINPGSGSANY 60  
QY 61 APFKKGLTMSRSDSTDTVTMTLTSLTSEDTAVYYCLQALKHWGQGLTVAVSS 114  
DB 61 APFQGLTMSRSDASTVTVMKLSLTSEDTAVYYCLQALKWVGQGLTVAVSS 114  
RESULT 13  
AAB18856  
ID AAB18856 standard; protein; 114 AA.  
XX  
XX AAB18856;  
XX  
XX 08-FEB-2001 (first entry)  
XX  
XX Amino acid sequence of anti-p53 antibody heavy chain clone 163.1.  
XX  
XX p53; antibody; immune response; vaccine; gene therapy; cancer;  
XX  
XX rheumatoid arthritis; coronary heart disease.  
XX  
XX Homo sapiens.  
XX  
XX WO200056770-A1.  
XX  
XX 28-SEP-2000.  
XX

PF 15-MAR-2000; 2000WO-AU000189.  
XX  
XX 19-MAR-1999; 99AU-00009321.  
XX  
XX (SVIN-) ST VINCENT'S HOSPITAL SYDNEY LTD.  
XX  
XX  
XX Ward RL, Coomber DMJ;  
XX WPI: 2000-638249/61.  
XX N-PSDB: AAA96133.  
XX  
XX  
XX Polynucleotides encoding anti-p53 antibodies, polypeptides and peptide fragments, useful in treatment and diagnosis of cancer, rheumatoid arthritis and coronary heart disease.  
XX  
XX Claim 30; Page 131; 163pp; English.  
XX  
XX The present sequence represents the heavy chain of an antibody reactive against p53. The antibody is obtained from a vertebrate host expressing an immune response against a naturally occurring disease. The antibodies are useful in pharmaceutical compositions, which additionally contain chelators, drugs, products, toxins and imaging markers e.g. radioisotopes or gadolinium. The polypeptide components of the antibodies are useful in vaccines, for inducing an immune response against a disease in a vertebrate, for treatment and/or prophylaxis of disease and for detection purposes. The nucleic acid sequences can be used to detect a disease as well as for gene therapy and recombinant production of the polypeptides. In particular, the following can be treated cancer, rheumatoid arthritis and coronary heart disease. Cancers include carcinogenic tumours, tumours of epithelial origin, e.g. colo-rectal cancer, breast cancer lung cancer, head and neck tumours, hepatic cancer, pancreatic cancer, ovarian cancer, gastric cancer, brain cancer, bladder cancer, prostate cancer and urinary/genital tract cancer, oesophageal cancer, mesenchymal tumours, e.g. sarcoma, and hemopoietic tumours, e.g. B cell lymphoma  
XX  
XX Sequence 114 AA;  
SQ  
Query Match 89.9%; Score 536; DB 3; Length 114;  
Best Local Similarity 88.6%; Pred. No. 3.4e-41;  
Matches 101; Conservative 8; Mismatches 5; Indels 0; Gaps 0;  
QY 1 VOLLESGAEVKGKPGASVTISCOASRODFSGQYIHWVROAPGCGFEMWGIINPGSGSANY 60  
DB 1 VOLLESGAEVKGKPGASVTISCOASROTFSGQYIHWVROAPGCGLEMMGVINPGSGSANY 60  
QY 61 APFKKGLTMSRSDSTDTVTMTLTSLTSEDTAVYYCLQALKHWGQGLTVAVSS 114  
DB 61 APFQGLTMSRSDASTVTVMKLSLTSEDTAVYYCLQALKWVGQGLTVAVSS 114  
RESULT 14  
AAB18872  
ID AAB18872 standard; protein; 114 AA.  
XX  
XX AAB18872;  
XX  
XX 08-FEB-2001 (first entry)  
XX  
XX Amino acid sequence of anti-p53 antibody heavy chain clone 163.16.  
XX  
XX p53; antibody; immune response; vaccine; gene therapy; cancer;  
XX  
XX rheumatoid arthritis; coronary heart disease.  
XX  
XX Homo sapiens.  
XX  
XX WO200056770-A1.  
XX  
XX 28-SEP-2000.  
XX  
XX 15-MAR-2000; 2000WO-AU000189.  
XX  
XX 19-MAR-1999; 99AU-00009321.  
XX

PA (SVIN-) ST VINCENT'S HOSPITAL SYDNEY LTD.  
XX  
PI Ward RL, Coomber DMJ;  
XX  
DR WPI; 2000-638249/61.  
XX N-PSDB; AAA96149.  
XX  
PT Polynucleotides encoding anti-p53 antibodies, polypeptides and peptide  
PT fragments, useful in treatment and diagnosis of cancer, rheumatoid  
PT arthritis and coronary heart disease.  
XX  
PS Claim 30; Page 147; 163pp; English.  
XX  
CC The present sequence represents the heavy chain of an antibody reactive  
CC against p53. The antibody is obtained from a vertebrate host expressing  
CC an immune response against a naturally occurring disease. The antibodies  
CC are useful in pharmaceutical compositions, which additionally contain  
CC chelators, drugs, produgs, toxins and imaging markers e.g. radioisotopes  
CC or gadolinium. The polypeptide components of the antibodies are useful in  
CC vaccines, for inducing an immune response against a disease in a  
CC vertebrate, for treatment and/or prophylaxis of disease and for detection  
CC purposes. The nucleic acid sequences can be used to detect a disease as  
CC well as for gene therapy and recombinant production of the polypeptides.  
CC In particular, the following can be treated cancer, rheumatoid arthritis  
CC and coronary heart disease. Cancers include carcinogenic tumours, tumours  
CC of epithelial origin, e.g. colo-rectal cancer, breast cancer lung cancer,  
CC head and neck tumours, hepatic cancer, pancreatic cancer, ovarian cancer,  
CC gastric cancer, brain cancer, bladder cancer, prostate cancer and  
CC urinary/genital tract cancer, oesophageal cancer, mesenchymal tumours,  
CC e.g. sarcoma, and hemopoietic tumours, e.g. B cell lymphoma  
XX  
SQ Sequence 114 AA;  
Query Match 89.9%; Score 536; DB 3; Length 114;  
Best Local Similarity 88.6%; Pred. No. 3,4e-41;  
Matches 101; Conservative 8; Mismatches 5; Indels 0; Gaps 0;  
QY 1 VOLLESGAEVKKRPGASVTISCOASRODFSGOYIHMYROAPGOGFEMWGIINPSSGSANY 60  
DB 1 VOLLESGAEMKRPASVTISCOASRQTFSGOYIHMYROAPGOGLEMMGIINPSSGSANY 60  
QY 61 APPFKGRLTMSRDSSTDTVTYMTLTSLTSEDTAVYYC LLAQAKHWGQGLTVAVSS 114  
DB 61 APFQGRSLMSRDSSTDTVTYMTLTSLTSEDTAVYYC LLAQAKHWGQGLTVAVSS 114  
RESULT 15  
AAV15127 ID AAV15127 standard; protein: 242 AA.  
XX  
AC AAV15127;  
XX  
DT 07-FEB-2000 (first entry)  
XX  
DE Anti-murine CTLA-4 M19 sFV.  
XX  
KM Anti-murine CTLA-4 sFV; M19 sFV; single chain antibody; murine CTLA4;  
KM membrane-associated protein; chimeric construct; extracellular domain;  
KM human CD8; ligand; activated T-cell; co-stimulatory signal; donor B7;  
KM recipient CD28; T-cell proliferation;  
KM xenograft-specific immunosuppression.  
XX  
OS Mus gp.  
OS Synthetic.  
XX  
XX Key Location/Qualifiers  
FT Misc-difference 208 /note= "Corresponds to atc codon"  
XX  
XX W09957266-A2.  
XX  
XX 11-NOV-1999.  
XX

PF 30-APR-1999; 99WO-GB001350.  
XX  
PR 30-APR-1998; 98GB-00009280.  
XX  
XX (IMCO-) IMPERIAL COLLEGE INNOVATIONS LTD.  
XX  
PA Lechler IR, Dorling A;  
XX  
PI WPI; 2000-038815/03.  
XX N-PSDB; AA228999.  
XX  
PT Inhibiting T-cell mediated rejection of xenotransplanted organs.  
XX  
PS Claim 9; Fig 11; 43pp; English.  
XX  
CC The present sequence is the anti-murine CTLA-4 sFV (M19 sFV). This is a  
CC membrane-associated protein which binds to CTLA-4. Chimeric constructs  
CC comprising DNA sequences encoding the extracellular domain of murine  
CC CTLA4 and human CD8 were used for the study of anti-CTLA4-sFV protein.  
CC The anti-hCTLA4 sFV functions as a ligand binding to CTLA-4 on activated  
CC T-cells and antagonises the co-stimulatory signal provided by the  
CC interaction between donor B7 and recipient CD28. Cells expressing the  
CC anti-hCTLA4 sFV failed to stimulate T-cell proliferation. This is used in  
CC xenograft-specific immunosuppression  
XX  
SQ Sequence 242 AA;  
Query Match 70.6%; Score 421; DB 3; Length 242;  
Best Local Similarity 69.7%; Pred. No. 2,2e-30;  
Matches 83; Conservative 12; Mismatches 18; Indels 6; Gaps 2;  
QY 1 VOLLESGAEVKKRPGASVTISCOASRODFSGOYIHMYROAPGOGFEMWGIINPSSGSANY 60  
DB 2 VOLV-QSGAEVKKRPGASVSKASGYTTSYIMHYROAPGOGLEMMGIINPSSGSANY 60  
QY 61 APPFKGRLTMSRDSSTDTVTYMTLTSLTSEDTAVYYC LLAQAKHWGQGLTVAVSS 114  
DB 61 AQFQGRVYMTTRDSTSTYVMEISLRSSEDTAVYYCARVAPVYNTLVFWGQGLTVAVSS 119  
Search completed: November 9, 2005, 05:59:09  
Job time : 168 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 9, 2005, 05:52:17 : Search time 165 Seconds  
(without alignments)  
289.083 Million cell updates/sec

Title: US-09-936-964A-36

Perfect score: 1 VQLLEGSGAEVKRGASVTI.....YCLLQALKHWGCTLVAVSS 114

Sequence: 1 VQLLEGSGAEVKRGASVTI.....YCLLQALKHWGCTLVAVSS 114

Scoring table: Gapop 10.0, Gapext 0.5

Searched: 1867879 seqs, 41849474 residues

Total number of hits satisfying chosen parameters: 1867879

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%

Listing first 45 summaries

Database:

Published Applications AA:\*

- 1: /cgn2\_6/ptodata/1/pubppaa/US07\_PUBCOMB.pep.\*
- 2: /cgn2\_6/ptodata/1/pubppaa/US06\_NEW\_PUB.pep.\*
- 3: /cgn2\_6/ptodata/1/pubppaa/US06\_NEW\_PUB.pep.\*
- 4: /cgn2\_6/ptodata/1/pubppaa/US06\_PUBCOMB.pep.\*
- 5: /cgn2\_6/ptodata/1/pubppaa/US07\_NEW\_PUB.pep.\*
- 6: /cgn2\_6/ptodata/1/pubppaa/US07\_PUBCOMB.pep.\*
- 7: /cgn2\_6/ptodata/1/pubppaa/US08\_NEW\_PUB.pep.\*
- 8: /cgn2\_6/ptodata/1/pubppaa/US08\_PUBCOMB.pep.\*
- 9: /cgn2\_6/ptodata/1/pubppaa/US09A\_PUBCOMB.pep.\*
- 10: /cgn2\_6/ptodata/1/pubppaa/US09B\_PUBCOMB.pep.\*
- 11: /cgn2\_6/ptodata/1/pubppaa/US09C\_PUBCOMB.pep.\*
- 12: /cgn2\_6/ptodata/1/pubppaa/US09C\_PUBCOMB.pep.\*
- 13: /cgn2\_6/ptodata/1/pubppaa/US10A\_PUBCOMB.pep.\*
- 14: /cgn2\_6/ptodata/1/pubppaa/US10B\_PUBCOMB.pep.\*
- 15: /cgn2\_6/ptodata/1/pubppaa/US10C\_PUBCOMB.pep.\*
- 16: /cgn2\_6/ptodata/1/pubppaa/US10D\_PUBCOMB.pep.\*
- 17: /cgn2\_6/ptodata/1/pubppaa/US10E\_PUBCOMB.pep.\*
- 18: /cgn2\_6/ptodata/1/pubppaa/US10F\_PUBCOMB.pep.\*
- 19: /cgn2\_6/ptodata/1/pubppaa/US10G\_PUBCOMB.pep.\*
- 20: /cgn2\_6/ptodata/1/pubppaa/US11\_NEW\_PUB.pep.\*
- 21: /cgn2\_6/ptodata/1/pubppaa/US60\_NEW\_PUB.pep.\*
- 22: /cgn2\_6/ptodata/1/pubppaa/US60\_PUBCOMB.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	418	70.1	142	US-10-171-452A-2	Sequence 2, Appl1
2	418	70.1	142	US-10-353-708-2	Sequence 2, Appl1
3	418	70.1	142	US-10-731-984-36	Sequence 36, Appl1
4	414	69.5	255	US-09-880-748-1156	Sequence 1156, Ap
5	414	69.5	255	US-10-293-418-1156	Sequence 1156, Ap
6	413.5	69.4	245	US-09-880-748-11919	Sequence 1919, Ap
7	413.5	69.4	245	US-10-293-418-11919	Sequence 1919, Ap
8	412	69.1	117	US-10-688-925-16	Sequence 16, Appl1
9	412	69.1	117	US-10-688-925-16	Sequence 28, Appl1
10	412	69.1	249	US-10-688-925-14	Sequence 14, Appl1
11	412	69.1	249	US-10-688-925-26	Sequence 26, Appl1

12	411.5	69.0	241	US-10-935-290-72	Sequence 72, Appl1
13	410	68.8	248	US-09-880-748-2091	Sequence 2091, Ap
14	410	68.8	248	US-10-293-418-2091	Sequence 2091, Ap
15	409	68.6	248	US-09-880-748-1178	Sequence 1178, Ap
16	409	68.6	248	US-10-293-418-1178	Sequence 1178, Ap
17	408.5	68.5	125	US-10-466-242-13	Sequence 13, Appl1
18	408.5	68.5	249	US-09-880-748-1290	Sequence 1290, Ap
19	408.5	68.5	249	US-09-880-748-1290	Sequence 1290, Ap
20	408.5	68.5	249	US-10-293-418-1290	Sequence 1290, Ap
21	408.5	68.5	251	US-09-880-748-1459	Sequence 1459, Ap
22	408.5	68.5	251	US-10-293-418-1459	Sequence 1459, Ap
23	408.5	68.5	254	US-09-880-748-1983	Sequence 1983, Ap
24	408.5	68.5	254	US-10-293-418-1983	Sequence 1983, Ap
25	406.5	68.5	254	US-09-880-748-1983	Sequence 1983, Ap
26	407	68.3	258	US-09-880-748-2090	Sequence 2090, Ap
27	407	68.3	258	US-10-293-418-2090	Sequence 2090, Ap
28	406	68.1	118	US-10-466-242-29	Sequence 29, Appl1
29	403.5	67.7	243	US-09-880-748-1947	Sequence 1947, Ap
30	403.5	67.7	243	US-10-293-418-1947	Sequence 1947, Ap
31	403.5	67.7	254	US-09-880-748-1961	Sequence 1961, Ap
32	403.5	67.7	254	US-10-293-418-1961	Sequence 1961, Ap
33	402.5	67.5	114	US-10-309-762-141	Sequence 141, Appl
34	402	67.4	253	US-09-880-748-1359	Sequence 1359, Ap
35	402	67.4	253	US-10-293-418-1359	Sequence 1359, Ap
36	401	67.3	123	US-11-039-767-14	Sequence 14, Appl1
37	399.5	67.0	245	US-10-943-197-5	Sequence 5, Appl1
38	399	66.9	247	US-09-880-748-1899	Sequence 1899, Ap
39	399	66.9	247	US-10-293-418-1899	Sequence 1899, Ap
40	399	66.9	248	US-09-880-748-959	Sequence 959, Appl
41	399	66.9	248	US-10-293-418-959	Sequence 959, Appl
42	399	66.9	256	US-09-880-748-1967	Sequence 1967, Ap
43	399	66.9	126	US-10-293-418-1967	Sequence 1967, Ap
44	398.5	66.9	132	US-09-811-737-10	Sequence 10, Appl1
45	398.5	66.9	260	US-09-811-737-16	Sequence 16, Appl1

#### ALIGNMENTS

RESULT 1  
US-10-171-452A-2  
: Sequence 2, Appl1 Application US/10171452A  
: Publication NO. US20030108518A1  
: GENERAL INFORMATION:  
: APPLICANT: Frewin, Mark  
: APPLICANT: Waldmann, Herman  
: APPLICANT: Gorman, Scott  
: APPLICANT: Hale, Geoff  
: APPLICANT: Rao, Patricia  
: APPLICANT: Kornaga, Tadeusz  
: APPLICANT: Ringler, Douglas  
: APPLICANT: Cobbold, Stephen  
: APPLICANT: Winsor-Hines, Dawn  
: TITLE OF INVENTION: TRX1 Antibody and Uses Therefor  
: FILE REFERENCE: 695458-59  
: CURRENT APPLICATION NUMBER: US/10/171,452A  
: PRIOR FILING DATE: 2003-02-10  
: PRIOR APPLICATION NUMBER: US60/373,471  
: PRIOR FILING DATE: 2002-04-18  
: PRIOR APPLICATION NUMBER: US60/373,470  
: PRIOR FILING DATE: 2002-04-18  
: PRIOR APPLICATION NUMBER: US60/345,194  
: PRIOR FILING DATE: 2002-10-19  
: PRIOR APPLICATION NUMBER: GB0122724.8  
: PRIOR FILING DATE: 2001-09-20  
: PRIOR APPLICATION NUMBER: GB0114517.6  
: PRIOR FILING DATE: 2001-06-14  
: NUMBER OF SEQ ID NOS: 60  
: SEQ ID NO 2  
: LENGTH: 142  
: TYPE: PRT  
: ORGANISM: Homo sapiens  
: US-10-171-452A-2

[illegible]

```

RESULT 2
US-10-353-708-2
: Sequence 2, Application US/10353708
: Publication No. US20030219403A1
: GENERAL INFORMATION:
: APPLICANT: Frewin, Mark
: APPLICANT: Waldmann, Herman
: APPLICANT: Gorman, Scott
: APPLICANT: Hale, Geoff
: APPLICANT: Rao, Patricia
: APPLICANT: Kornaga, Tadeusz
: APPLICANT: Ringler, Douglas
: APPLICANT: Cobbold, Stephen
: APPLICANT: Winsor-Hines, Dawn
: TITLE OR INVENTION: Compositions and Methods of Tolerizing a Primate to an Antigen
: FILE REFERENCE: 695458-73
: CURRENT APPLICATION NUMBER: US/10/353,708
: PRIOR FILING DATE: 2003-01-29
: PRIOR APPLICATION NUMBER: US10/171,452
: PRIOR FILING DATE: 2002-06-13
: PRIOR APPLICATION NUMBER: US60/373,471
: PRIOR FILING DATE: 2002-04-18
: PRIOR APPLICATION NUMBER: US60/373,470
: PRIOR FILING DATE: 2002-04-18
: PRIOR APPLICATION NUMBER: US60/345,194
: PRIOR FILING DATE: 2002-10-19
: PRIOR APPLICATION NUMBER: GB0122724.8
: PRIOR FILING DATE: 2001-09-20
: PRIOR APPLICATION NUMBER: GB0114517.6
: PRIOR FILING DATE: 2001-06-14
: NUMBER OF SEQ ID NOS: 60
: SEQ ID NO 2
: LENGTH: 142
: TYPE: PRT
: ORGANISM: Homo sapiens
US-10-353-708-2

```

	Query Match	70.1%	Score 418;	DB 15;	Length 142;
	Best Local Similarity	63.8%;	Pred. No. 2.7e-31;		
	Matches	81;	Conservative 15;	Mismatches 17;	Indels 14; Gaps 2.
Qy	1 VQLLEQSAAEYKRPASVLTISCOASROFSGCYIHMYRQAPQGCFEMMGITNPSGGSANY 60				
Dd	12 VQLV-QSAAEAYKKPPASVKVSCSKSGYFTNTNYMHMVRAQPGGLEMMGITNPSGNSINY 70				
Qy	61 APEKGRILTMSRDSDTDVTVMTLTSLTSEDTAVVYC-----LLOALGHMGG 107				
Dd	71 AQKFGGRATMRDSTSTVYMELSLRSEDFAVVYCAREKLATTIFGVLIITGMDDYWGCG 130				
Qy	108 TLVAVSS 114				
Dd	131 TLTVTSS 137				

### RESULT 3

```

US-10-731-984-36
? Sequence 36, Application US/10731984
? Publication No. US20040175381A1
? GENERAL INFORMATION:
? APPLICANT: WINDSOR-HINES, Dawn
? APPLICANT: RAO, Patricia
? APPLICANT: RINGLER, Douglas J.
? TITLE OF INVENTION: INDUCING TOLERANCE IN PRIMATES
? FILE REFERENCE: T1N-022
? CURRENT APPLICATION NUMBER: US/10/731,984
? CURRENT FILING DATE: 2003-12-09
? PRIOR APPLICATION NUMBER: 60/431839
? PRIOR FILING DATE: 2002-12-09
? NUMBER OF SEQ ID NOS: 70
? SOFTWARE: FastSeq for Windows Version 4.0
? SEQ ID NO 36
? LENGTH: 142
? TYPE: PR1
? ORGANISM: Artificial Sequence
? FEATURE:
? OTHER INFORMATION: Synthetic Oligonucleotide
US-10-731-984-36

Query Match      70.1%, Score 418, DB 16, Length 142,
Best Local Similarity 63.8%, Pred. No. 2.7e-31,
Matches 81, Conservative 15, Mismatches 17, Indels 14, Gaps 2

```

QY 61 APEFKRLNMSDSSDTWMTLTSTSEDPNAVYYC-----LLQALKHGQG 107  
|||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||  
Db 71 AQCFQGRVMTMDTISTIVYMELSLRSBDPAVYYCARAKLATTIFGVLIITGMIDWGG 130  
  
QY 108 TLVAASS 114  
|||::|||  
Db 131 FLTVASS 137

```

RESULT 4
US-09-880-748-1156
/ Sequence 1156, Application US/09880748
/ Publication No. US20030059937A1
/ GENERAL INFORMATION:
/ APPLICANT: Ruben et al.
/ TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
/ FILE REFERENCE: PF523
/ CURRENT APPLICATION NUMBER: US/09/880,748
/ CURRENT FILING DATE: 2001-06-15
/ PRIOR APPLICATION NUMBER: 60/212,210
/ PRIOR FILING DATE: 2000-06-15
/ PRIOR APPLICATION NUMBER: 60/240,816
/ PRIOR FILING DATE: 2000-10-17
/ PRIOR APPLICATION NUMBER: 60/276,248
/ PRIOR FILING DATE: 2001-03-16
/ PRIOR APPLICATION NUMBER: 60/272,379
/ PRIOR FILING DATE: 2001-03-21
/ PRIOR APPLICATION NUMBER: 60/293,499
/ PRIOR FILING DATE: 2001-05-25
/ NUMBER OF SEQ ID NOS: 3239
/ SOFTWARE: PatentIn Ver. 2.0
/ SEQ ID NO 1156
/ LENGTH: 255
/ TYPE: PRT
/ ORGANISM: Homo sapiens
US-09-880-748-1156

```

Query Match	69.5%	Score 414;	DB 10;	Length 255;
Best Local Similarity	63.2%;	Pred. No. 1.2e-30;		
Matches	79;	Conservative 14;	Mismatches 18;	Indels 14;
Gaps	1			

```
Db 4 LQSGAEVKKRPGASVTKSCASGYTFTSYHWRQAPGQGLEMMGIINPSGGSSTYAK 63
      |||:|||||:|||||:|:|:|||||:|||||:|||||:|||||:|||||:|||||:
Qy 64 FKGLTMSRDSSTDTVTMTLTSLTSEPTAVYYCL-----LQALKHMGQGLT 109
      |||:|||||:|||||:|:|:|||||:|||||:|||||:|||||:|||||:
Db 64 FQGVVTRDTRDTSITVYMELSLRSEDTAVYYCARGGEDYDILGTGYFGLGVYDYGQGT 123
      |||:|||||:|||||:|:|:|||||:|||||:|||||:|||||:|||||:
Qy 110 VAWS 114
      |||:|||||:|||||:|:|:|||||:|||||:|||||:|||||:|||||:
Db 124 VTWS 128

RESULT 5
US-10-293-418-1156
; Sequence 1156, Application US/10293418
; Publication No. US20030223996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PFS23P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1156
; LENGTH: 255
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-1156

Query Match 69.5%; Score 414; DB 15; Length 255;
Best Local Similarity 63.2%; Pred. No. 1.2e-30;
Matches 79; Conservative 14; Mismatches 18; Indels 14; Gaps 1;

Qy 4 LEQSGAEVKKRPGASVTKSCASRODFSGQYIHWWRQAPGQGFEMMGIINPSGGSANYAPK 63
      |||:|||||:|||||:|:|:|||||:|||||:|||||:|||||:|||||:
Db 4 LQSGAEVKKRPGASVTKSCASGYTFTSYHWRQAPGQGLEMMGIINPSGGSSTYAK 63
      |||:|||||:|||||:|:|:|||||:|||||:|||||:|||||:|||||:
Qy 64 FKGLTMSRDSSTDTVTMTLTSLTSEPTAVYYCL-----LQALKHMGQGLT 109
      |||:|||||:|||||:|:|:|||||:|||||:|||||:|||||:|||||:
Db 64 FQGVVTRDTRDTSITVYMELSLRSEDTAVYYCARGGEDYDILGTGYFGLGVYDYGQGT 123
      |||:|||||:|||||:|:|:|||||:|||||:|||||:|||||:|||||:
Qy 110 VAWS 114
      |||:|||||:|||||:|:|:|||||:|||||:|||||:|||||:|||||:
Db 124 VTWS 128

RESULT 6
US-09-880-748-1919
; Sequence 1919, Application US/09880748
; Publication No. US2003005937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PFS23
; CURRENT APPLICATION NUMBER: US/09/880,748
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
```

```
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1919
; LENGTH: 245
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-1919

Query Match 69.4%; Score 413.5; DB 10; Length 245;
Best Local Similarity 66.4%; Pred. No. 1.2e-30;
Matches 81; Conservative 14; Mismatches 18; Indels 9; Gaps 2;

Qy 1 VOLLEQSGAEVKKRPGASVTKSCASRODFSGQYIHWWRQAPGQGFEMMGIINPSGGSANY 60
      |||:|||||:|||||:|:|:|||||:|||||:|||||:|||||:|||||:
Db 2 VOLV-QSGAEVKKRPGASVTKSCASGYTFTSYHWRQAPGQGLEMMGIINPSGGSSTY 60
      |||:|||||:|||||:|:|:|||||:|||||:|||||:|||||:|||||:
Qy 61 APFKGRITMSRDSSTDTVTMTLTSLTSEPTAVYYCL-----LQALKHMGQGLT 112
      |||:|||||:|||||:|:|:|||||:|||||:|||||:|||||:|||||:
Db 61 AOKFQGVVTRDTRDTSITVYMELSLRSEDTAVYYCARDLGSGYFSRYPDYWGQGLTV 120
      |||:|||||:|||||:|:|:|||||:|||||:|||||:|||||:|||||:
Qy 113 SS 114
      |||:|||||:|||||:|:|:|||||:|||||:|||||:|||||:|||||:
Db 121 SS 122

RESULT 7
US-10-293-418-1919
; Sequence 1919, Application US/10293418
; Publication No. US20030223996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PFS23P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1919
; LENGTH: 245
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-1919

Query Match 69.4%; Score 413.5; DB 15; Length 245;
Best Local Similarity 66.4%; Pred. No. 1.2e-30;
Matches 81; Conservative 14; Mismatches 18; Indels 9; Gaps 2;

Qy 1 VOLLEQSGAEVKKRPGASVTKSCASRODFSGQYIHWWRQAPGQGFEMMGIINPSGGSANY 60
      |||:|||||:|||||:|:|:|||||:|||||:|||||:|||||:|||||:
Db 1 VOLLEQSGAEVKKRPGASVTKSCASRODFSGQYIHWWRQAPGQGFEMMGIINPSGGSANY 60
      |||:|||||:|||||:|:|:|||||:|||||:|||||:|||||:|||||:
```

Db 2 VOLV-QSGAEVKKPGASVKASCASGYTFTSYMHVWRQAPQGQLEWMGIINPSSGSTSY 60  
QY 61 APFKGRLTMSRSDSDTYVMTLTSLTSEPTAVYYC-----LLOALKHMGQTLVAVS 112  
Db 61 AQKFGQRTVMTSDTSTVYMWELSLRSEDTAVYYCARDLSGYSFRRYPDYGQGLTVVSS 120

QY 113 SS 114  
Db 121 SS 122

RESULT 8  
US-10-688-925-16  
; Sequence 16, Application US/10688925  
; Publication No. US20040142382A1  
; GENERAL INFORMATION:  
; APPLICANT: Veldman, Geertuida et al.  
; TITLE OF INVENTION: NEUTRALIZING ANTIBODIES AGAINST GDF 8 AND USES THEREFOR  
; FILE REFERENCE: 08702.0020-00000  
; CURRENT APPLICATION NUMBER: US/10/688,925  
; CURRENT FILING DATE: 2003-10-21  
; NUMBER OF SEQ ID NOS: 54  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 16  
; LENGTH: 117  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-688-925-16

Query Match 69.1%; Score 412; DB 16; Length 117;  
Best Local Similarity 69.2%; Pred. No. 8e-31;  
Matches 81; Conservative 12; Mismatches 20; Indels 4; Gaps 2;  
QY 1 VOLLEQSGAEVKKPGASVTTISCOASRQDPSGQYIHVWRQAPQGQFPEWMGIINPSSGSANY 60  
Db 2 VOLV-QSGAEVKKPGASVKASCASGYTFTSYMHVWRQAPQGQLEWMGIINPSSGSTSY 60  
QY 61 APFKGRLTMSRSDSDTYVMTLTSLTSEPTAVYYCCLQ--ALKHMGQTLVAVSS 114  
Db 61 AQKFGQRTVMTSDTSTVYMWELSLRSEDTAVYYCARDENMGFDPWGQGLTVVSS 117

RESULT 9  
US-10-688-925-28  
; Sequence 28, Application US/10688925  
; Publication No. US20040142382A1  
; GENERAL INFORMATION:  
; APPLICANT: Veldman, Geertuida et al.  
; TITLE OF INVENTION: NEUTRALIZING ANTIBODIES AGAINST GDF 8 AND USES THEREFOR  
; FILE REFERENCE: 08702.0020-00000  
; CURRENT APPLICATION NUMBER: US/10/688,925  
; CURRENT FILING DATE: 2003-10-21  
; NUMBER OF SEQ ID NOS: 54  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 28  
; LENGTH: 117  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-688-925-28

Query Match 69.1%; Score 412; DB 16; Length 117;  
Best Local Similarity 69.2%; Pred. No. 8e-31;  
Matches 81; Conservative 12; Mismatches 20; Indels 4; Gaps 2;  
QY 1 VOLLEQSGAEVKKPGASVTTISCOASRQDPSGQYIHVWRQAPQGQFPEWMGIINPSSGSANY 60  
Db 2 VOLV-QSGAEVKKPGASVKASCASGYTFTSYMHVWRQAPQGQLEWMGIINPSSGSTSY 60  
QY 61 APFKGRLTMSRSDSDTYVMTLTSLTSEPTAVYYCCLQ--ALKHMGQTLVAVSS 114  
Db 61 AQKFGQRTVMTSDTSTVYMWELSLRSEDTAVYYCARDENMGFDPWGQGLTVVSS 117

RESULT 10  
US-10-688-925-14  
; Sequence 14, Application US/10688925  
; Publication No. US20040142382A1  
; GENERAL INFORMATION:  
; APPLICANT: Veldman, Geertuida et al.  
; TITLE OF INVENTION: NEUTRALIZING ANTIBODIES AGAINST GDF 8 AND USES THEREFOR  
; FILE REFERENCE: 08702.0020-00000  
; CURRENT APPLICATION NUMBER: US/10/688,925  
; CURRENT FILING DATE: 2003-10-21  
; NUMBER OF SEQ ID NOS: 54  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 14  
; LENGTH: 249  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-688-925-14

Query Match 69.1%; Score 412; DB 16; Length 249;  
Best Local Similarity 69.2%; Pred. No. 1.7e-30;  
Matches 81; Conservative 12; Mismatches 20; Indels 4; Gaps 2;  
QY 1 VOLLEQSGAEVKKPGASVTTISCOASRQDPSGQYIHVWRQAPQGQFPEWMGIINPSSGSANY 60  
Db 2 VOLV-QSGAEVKKPGASVKASCASGYTFTSYMHVWRQAPQGQLEWMGIINPSSGSTSY 60  
QY 61 APFKGRLTMSRSDSDTYVMTLTSLTSEPTAVYYCCLQ--ALKHMGQTLVAVSS 114  
Db 61 AQKFGQRTVMTSDTSTVYMWELSLRSEDTAVYYCARDENMGFDPWGQGLTVVSS 117

RESULT 11  
US-10-688-925-26  
; Sequence 26, Application US/10688925  
; Publication No. US20040142382A1  
; GENERAL INFORMATION:  
; APPLICANT: Veldman, Geertuida et al.  
; TITLE OF INVENTION: NEUTRALIZING ANTIBODIES AGAINST GDF 8 AND USES THEREFOR  
; FILE REFERENCE: 08702.0020-00000  
; CURRENT APPLICATION NUMBER: US/10/688,925  
; CURRENT FILING DATE: 2003-10-21  
; NUMBER OF SEQ ID NOS: 54  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 26  
; LENGTH: 249  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-688-925-26

Query Match 69.1%; Score 412; DB 16; Length 249;  
Best Local Similarity 69.2%; Pred. No. 1.7e-30;  
Matches 81; Conservative 12; Mismatches 20; Indels 4; Gaps 2;  
QY 1 VOLLEQSGAEVKKPGASVTTISCOASRQDPSGQYIHVWRQAPQGQFPEWMGIINPSSGSANY 60  
Db 2 VOLV-QSGAEVKKPGASVKASCASGYTFTSYMHVWRQAPQGQLEWMGIINPSSGSTSY 60  
QY 61 APFKGRLTMSRSDSDTYVMTLTSLTSEPTAVYYCCLQ--ALKHMGQTLVAVSS 114  
Db 61 AQKFGQRTVMTSDTSTVYMWELSLRSEDTAVYYCARDENMGFDPWGQGLTVVSS 117

RESULT 12  
US-10-935-290-72  
; Sequence 72, Application US/10935290  
; Publication No. US20050069542A1  
; GENERAL INFORMATION:  
; APPLICANT: Baker et al.  
; TITLE OF INVENTION: Antibodies that Specifically Bind to GMPAD  
; FILE REFERENCE: PFS64P1  
; CURRENT APPLICATION NUMBER: US/10/935,290  
; CURRENT FILING DATE: 2004-09-08  
; PRIOR APPLICATION NUMBER: PCT/US03/09625

Query Match 69.1%; Score 412; DB 16; Length 249;  
Best Local Similarity 69.2%; Pred. No. 1.7e-30;  
Matches 81; Conservative 12; Mismatches 20; Indels 4; Gaps 2;  
QY 1 VOLLEQSGAEVKKPGASVTTISCOASRQDPSGQYIHVWRQAPQGQFPEWMGIINPSSGSANY 60  
Db 2 VOLV-QSGAEVKKPGASVKASCASGYTFTSYMHVWRQAPQGQLEWMGIINPSSGSTSY 60  
QY 61 APFKGRLTMSRSDSDTYVMTLTSLTSEPTAVYYCCLQ--ALKHMGQTLVAVSS 114  
Db 61 AQKFGQRTVMTSDTSTVYMWELSLRSEDTAVYYCARDENMGFDPWGQGLTVVSS 117

RESULT 13  
US-10-935-290-72  
; Sequence 72, Application US/10935290  
; Publication No. US20050069542A1  
; GENERAL INFORMATION:  
; APPLICANT: Baker et al.  
; TITLE OF INVENTION: Antibodies that Specifically Bind to GMPAD  
; FILE REFERENCE: PFS64P1  
; CURRENT APPLICATION NUMBER: US/10/935,290  
; CURRENT FILING DATE: 2004-09-08  
; PRIOR APPLICATION NUMBER: PCT/US03/09625



```
; PRIOR FILING DATE: 2003-03-28
; PRIOR APPLICATION NUMBER: 60/366,813
; PRIOR FILING DATE: 2002-04-01
; NUMBER OF SEQ ID NOS: 234
; SEQ ID NO 72
; LENGTH: 241
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: scfv protein GMBG46
US-10-935-290-72
```

```
Query Match          69.0%; Score 411.5; DB 17; Length 241;
Best Local Similarity 66.9%; Pred. No. 1.9e-30;
Matches 79; Conservative 17; Mismatches 17; Indels 5; Gaps 2;
```

```
QY 1 VOLLEQSGAEVKKRPGASVTISCOASRODFSGQYIHWYRQAPGQGFEMWGIINPSGGSANY 60
    |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 2 VOLV-QSGAEVKKRPGASVTKSCASGVTFTSYIHWYRQAPGQGLEMMGIINPSGGSITSY 60
    |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 APRFKGLTMSRDSSTDTVTMTLTSLTSEDTAVYCC---LLQALKIMGGCTLVAVSS 114
    |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AOKFGQSVTWTTRDTSTSTVYMWELSLRSEDTAVYFCARERFLRGMQVWGRTVTVSS 118
    |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
```

## RESULT 13

```
US-09-880-748-2091
; Sequence 2091, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2091
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-880-748-2091
```

```
Query Match          68.8%; Score 410; DB 10; Length 248;
Best Local Similarity 65.3%; Pred. No. 2.7e-30;
```

```
Matches 79; Conservative 17; Mismatches 17; Indels 8; Gaps 2;
```

```
QY 1 VOLLEQSGAEVKKRPGASVTISCOASRODFSGQYIHWYRQAPGQGFEMWGIINPSGGSANY 60
    |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 2 VOLV-QSGAEVKKRPGASVTKSCASGVTFTDYIHWYRQAPGQGLEMMGIINPSGGSITSY 60
    |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 APRFKGLTMSRDSSTDTVTMTLTSLTSEDTAVYCC-----HWGGCTLVAVS 113
    |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AOKFGQSVTWTTRDTSTSTVYMWELSLRSEDTAVYFCARSTLEVATDFDWGGCTVTVSS 120
    |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 114 S 114
    |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 121 S 121
    |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
```

```
RESULT 14
US-10-293-418-2091
; Sequence 2091, Application US/10293418
```

```
; Publication No. US20030223996A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P2
; CURRENT APPLICATION NUMBER: US/10/293,418
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 2091
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-418-2091
```

```
Query Match          68.8%; Score 410; DB 15; Length 248;
Best Local Similarity 65.3%; Pred. No. 2.7e-30;
Matches 79; Conservative 17; Mismatches 17; Indels 8; Gaps 2;
```

```
QY 1 VOLLEQSGAEVKKRPGASVTISCOASRODFSGQYIHWYRQAPGQGFEMWGIINPSGGSANY 60
    |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 2 VOLV-QSGAEVKKRPGASVTKSCASGVTFTDYIHWYRQAPGQGLEMMGIINPSGGSITSY 60
    |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 61 APRFKGLTMSRDSSTDTVTMTLTSLTSEDTAVYCC-----HWGGCTLVAVS 113
    |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 AOKFGQSVTWTTRDTSTSTVYMWELSLRSEDTAVYFCARSTLEVATDFDWGGCTVTVSS 120
    |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 114 S 114
    |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 121 S 121
    |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
```

## RESULT 15

```
US-09-880-748-1178
; Sequence 1178, Application US/09880748
; Publication No. US20030059937A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523
; CURRENT APPLICATION NUMBER: US/09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1178
; LENGTH: 248
; TYPE: PRT
; ORGANISM: Homo sapiens
```

US-09-880-748-1178

Query Match	68.6%;	Score 409;	DB 10;	Length 248;
Best Local Similarity	64.8%;	Prod NO. 3 30-30;		

Best Local Similarity 64.88; Pred. No. 3.3e-30;

Matches 81; Conservative 14; Mismatches 18; Indels 12; Gaps 2;

QY 1 VQLLEQSGAEVKRPGASVTISCSQASRDPFGSQYIHWKQAPGGQFEMMGIIINPGGSANY 60  
|||:|||||:|||||:|||||:|||||:|  
Dp 2 VQLV-QSGAEVKKPGASVVKSCASGYTFTSYMHWKQAPGGQLEMMGIINPGGSSTSY 60

2 VQLV-QSGAEVKKPGASVKVSCKASGYTFTSYMHVVRQAPGQGLEWMGIINPSGGSTSY 60

Dy           61 A P K K G R L M S R D S T D Y V W I T L T S I T S E D N A V Y C L -----L Q A L K H W G O G T L 109  
| : | : | : | : | : | : | : | : | : | : | : | : | :  
Db          61 A Q K F G R V M T R D T S T S T V Y M E L S L R S E D N A V Y Y C A R E H Y D I L T G Y S L L G M D V W G R G T L 120

61 A Q K F G R V T M R D T S T V M E L S L R S E D T A V Y C A R E H Y D I L T G Y S L L G M D V W G R G T L 120

QY 110 VAVSS 114

Db 121 VTVSS 125

Search completed: November 9, 2005, 05:55:11  
Job time : 166 secs

Job time : 166 secs